<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd"><coredata><prism:url>http://api.elsevier.com/content/article/pii/S0168365913008766</prism:url><dc:identifier>doi:10.1016/j.jconrel.2013.10.027</dc:identifier><eid>1-s2.0-S0168365913008766</eid><prism:doi>10.1016/j.jconrel.2013.10.027</prism:doi><pii>S0168-3659(13)00876-6</pii><dc:title>A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8+ T-cell-mediated anti-tumor immunity </dc:title><prism:publicationName>Journal of Controlled Release</prism:publicationName><prism:aggregationType>Journal</prism:aggregationType><prism:issn>01683659</prism:issn><prism:volume>173</prism:volume><prism:startingPage>158</prism:startingPage><prism:endingPage>165</prism:endingPage><prism:pageRange>158-165</prism:pageRange><dc:format>text/xml</dc:format><prism:coverDate>2014-01-10</prism:coverDate><prism:coverDisplayDate>10 January 2014</prism:coverDisplayDate><prism:copyright>Copyright © 2013 The Authors. Published by Elsevier B.V.</prism:copyright><prism:publisher>The Authors. Published by Elsevier B.V.</prism:publisher><dc:creator>Song, Ying-Chyi</dc:creator><dc:creator>Cheng, Han-Yin</dc:creator><dc:creator>Leng, Chih-Hsiang</dc:creator><dc:creator>Chiang, Sheng-Kuo</dc:creator><dc:creator>Lin, Chih-Wei</dc:creator><dc:creator>Chong, Pele</dc:creator><dc:creator>Huang, Ming-Hsi</dc:creator><dc:creator>Liu, Shih-Jen</dc:creator><dc:description>AbstractPELC is a novel emulsion-type adjuvant that contains the bioresorbable polymer poly (ethylene glycol)-block-poly (lactide-co-ε-caprolactone) (PEG-b-PLACL), Span®85 and squalene. To investigate whether PELC is able to enhance CTL responses of antigens for treating tumor, peptides or protein antigens derived from HPV16 E7 were formulated with PELC nanoparticles and CpG oligodeoxynucleotide. We identified that PELC formulation could delay the release of antigens in vitro and in vivo. We assessed the immunogenicity of an H-2Db-restricted CTL epitope RAHYNIVTF (RAH) formulated with PELC or PELC/CpG and investigated the ability of these formulations to promote tumor regression. Following a single-dose subcutaneous injection in mice, we found that the RAH peptide formulated with PELC/CpG (RAH/PELC/CpG) resulted in increased numbers of IFN-γ-secreting cells and RAH-specific CD8+ T cells and an enhanced cytotoxic T cell response compared with RAH formulated with PELC or CpG alone. The tumor-bearing mice received a single-dose injection of RAH/PELC/CpG, which induced complete tumor regression. These results demonstrated that peptide antigen formulated with PELC/CpG nanoparticles is feasible for cancer immunotherapy.</dc:description><openaccess>1</openaccess><openaccessArticle>true</openaccessArticle><openaccessType>Full</openaccessType><openArchiveArticle>false</openArchiveArticle><openaccessSponsorName/><openaccessSponsorType>Author</openaccessSponsorType><openaccessUserLicense>http://creativecommons.org/licenses/by-nc-sa/3.0/</openaccessUserLicense><dcterms:subject>Adjuvant</dcterms:subject><dcterms:subject>Immunotherapy</dcterms:subject><dcterms:subject>Human papillomavirus (HPV)</dcterms:subject><dcterms:subject>Cervical cancer</dcterms:subject><dcterms:subject>CpG oligodeoxynucleotide</dcterms:subject><link rel="self" href="http://api.elsevier.com/content/article/pii/S0168365913008766"/><link rel="scidir" href="http://www.sciencedirect.com/science/article/pii/S0168365913008766"/></coredata><objects><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3030" height="1282" size="304840">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913008766-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1039" height="855" size="85981">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913008766-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1732" height="1941" size="283761">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913008766-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1732" height="2659" size="549353">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913008766-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1614" height="4401" size="672920">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913008766-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2213" height="622" size="250274">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913008766-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="684" height="289" size="40473">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913008766-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="391" height="322" size="29095">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913008766-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="391" height="438" size="43078">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913008766-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="391" height="600" size="68617">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913008766-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="364" height="993" size="84367">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913008766-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="500" height="141" size="26285">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913008766-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="93" size="3457">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913008766-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="199" height="164" size="3773">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913008766-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="146" height="164" size="3809">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913008766-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="106" height="163" size="6520">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913008766-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="60" height="164" size="2160">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913008766-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="62" size="5730">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913008766-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="230680">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913008766-mmc1.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>84888319887</scopus-id><scopus-eid>2-s2.0-84888319887</scopus-eid><pubmed-id>24177312</pubmed-id><link rel="abstract" href="http://api.elsevier.com/content/abstract/scopus_id/84888319887"/><originalText><xocs:doc xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd" xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://be-prod3a/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta><xocs:content-family>serial</xocs:content-family><xocs:content-type>JL</xocs:content-type><xocs:cid>271103</xocs:cid><xocs:ssids><xocs:ssid type="alllist">291210</xocs:ssid><xocs:ssid type="subj">291681</xocs:ssid><xocs:ssid type="subj">291789</xocs:ssid><xocs:ssid type="content">31</xocs:ssid><xocs:ssid type="oa">90</xocs:ssid></xocs:ssids><xocs:srctitle>Journal of Controlled Release</xocs:srctitle><xocs:normalized-srctitle>JOURNALCONTROLLEDRELEASE</xocs:normalized-srctitle><xocs:orig-load-date yyyymmdd="20131029">2013-10-29</xocs:orig-load-date><xocs:available-online-date yyyymmdd="20131029">2013-10-29</xocs:available-online-date><xocs:ew-transaction-id>2014-10-01T13:52:14</xocs:ew-transaction-id><xocs:eid>1-s2.0-S0168365913008766</xocs:eid><xocs:pii-formatted>S0168-3659(13)00876-6</xocs:pii-formatted><xocs:pii-unformatted>S0168365913008766</xocs:pii-unformatted><xocs:doi>10.1016/j.jconrel.2013.10.027</xocs:doi><xocs:item-stage>S300</xocs:item-stage><xocs:item-version-number>S300.3</xocs:item-version-number><xocs:item-weight>FULL-TEXT</xocs:item-weight><xocs:hub-eid>1-s2.0-S0168365913X00215</xocs:hub-eid><xocs:timestamp yyyymmdd="20150514">2015-05-14T05:17:02.743021-04:00</xocs:timestamp><xocs:dco>0</xocs:dco><xocs:tomb>0</xocs:tomb><xocs:date-search-begin>20140110</xocs:date-search-begin><xocs:year-nav>2014</xocs:year-nav><xocs:indexeddate epoch="1383004800">2013-10-29T00:00:00Z</xocs:indexeddate><xocs:articleinfo>absattachment articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid fundingbodyid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight oauserlicense openaccess openarchive pg pgfirst pglast pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder sponsoredaccesstype srctitle srctitlenorm srctype ssids alllist content oa subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure e-component body acknowledge affil articletitle auth authfirstini authfull authkeywords authlast grantnumber grantsponsor orcid primabst ref specialabst</xocs:articleinfo><xocs:issns><xocs:issn-primary-formatted>0168-3659</xocs:issn-primary-formatted><xocs:issn-primary-unformatted>01683659</xocs:issn-primary-unformatted></xocs:issns><xocs:sponsored-access-type>UNLIMITED</xocs:sponsored-access-type><xocs:funding-body-id>NONE</xocs:funding-body-id><xocs:crossmark is-crossmark="1">true</xocs:crossmark><xocs:vol-first>173</xocs:vol-first><xocs:volume-list><xocs:volume>173</xocs:volume></xocs:volume-list><xocs:suppl>C</xocs:suppl><xocs:vol-iss-suppl-text>Volume 173</xocs:vol-iss-suppl-text><xocs:sort-order>21</xocs:sort-order><xocs:first-fp>158</xocs:first-fp><xocs:last-lp>165</xocs:last-lp><xocs:pages><xocs:first-page>158</xocs:first-page><xocs:last-page>165</xocs:last-page></xocs:pages><xocs:cover-date-orig><xocs:start-date>20140110</xocs:start-date></xocs:cover-date-orig><xocs:cover-date-text>10 January 2014</xocs:cover-date-text><xocs:cover-date-start>2014-01-10</xocs:cover-date-start><xocs:cover-date-year>2014</xocs:cover-date-year><xocs:hub-sec><xocs:hub-sec-title>Nanomedicine</xocs:hub-sec-title></xocs:hub-sec><xocs:document-type>article</xocs:document-type><xocs:document-subtype>fla</xocs:document-subtype><xocs:copyright-line>Copyright © 2013 The Authors. Published by Elsevier B.V.</xocs:copyright-line><xocs:normalized-article-title>ANOVELEMULSIONTYPEADJUVANTCONTAININGCPGOLIGODEOXYNUCLEOTIDESENHANCESCD8TCELLMEDIATEDANTITUMORIMMUNITY</xocs:normalized-article-title><xocs:normalized-first-auth-surname>SONG</xocs:normalized-first-auth-surname><xocs:normalized-first-auth-initial>Y</xocs:normalized-first-auth-initial><xocs:item-toc><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>1</xocs:item-toc-label><xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2</xocs:item-toc-label><xocs:item-toc-section-title>Materials and methods</xocs:item-toc-section-title><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.1</xocs:item-toc-label><xocs:item-toc-section-title>Materials</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.2</xocs:item-toc-label><xocs:item-toc-section-title>The preparation of PELC</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.3</xocs:item-toc-label><xocs:item-toc-section-title><ce:italic>In vivo</ce:italic> fluorescence imaging</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.4</xocs:item-toc-label><xocs:item-toc-section-title>Animals</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.5</xocs:item-toc-label><xocs:item-toc-section-title>The detection of peptide-specific CD8<ce:sup loc="post">+</ce:sup> T cells</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.6</xocs:item-toc-label><xocs:item-toc-section-title><ce:italic>In vivo</ce:italic> cytolysis assay</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.7</xocs:item-toc-label><xocs:item-toc-section-title>Tumor regression study in mice</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.8</xocs:item-toc-label><xocs:item-toc-section-title>Statistical analysis</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3</xocs:item-toc-label><xocs:item-toc-section-title>Results</xocs:item-toc-section-title><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.1</xocs:item-toc-label><xocs:item-toc-section-title>The formulation of antigens with PELC</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.2</xocs:item-toc-label><xocs:item-toc-section-title>PELC delay the release of antigen <ce:italic>in vivo</ce:italic></xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.3</xocs:item-toc-label><xocs:item-toc-section-title>The RAH peptide formulated with PELC and/or CpG enhances specific CD8<ce:sup loc="post">+</ce:sup> T cells</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.4</xocs:item-toc-label><xocs:item-toc-section-title>The RAH peptide formulated with PELC and CpG elicits a CTL response</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.5</xocs:item-toc-label><xocs:item-toc-section-title>The RAH peptide formulated with PELC and/or CpG induces an anti-tumor effect</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>4</xocs:item-toc-label><xocs:item-toc-section-title>Discussion</xocs:item-toc-section-title><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>4.1</xocs:item-toc-label><xocs:item-toc-section-title>The development of a W/O/W emulsion-type adjuvant (PELC) for cancer immunotherapy</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>4.2</xocs:item-toc-label><xocs:item-toc-section-title>The incorporation of a TLR ligand in the PELC formulation enhanced anti-tumor activity</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>5</xocs:item-toc-label><xocs:item-toc-section-title>Conclusion</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:acknowledgment"><xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:bibliography"><xocs:item-toc-section-title>References</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc><xocs:references><xocs:ref-info refid="rf0005"><xocs:ref-normalized-surname>WALBOOMERS</xocs:ref-normalized-surname><xocs:ref-pub-year>1999</xocs:ref-pub-year><xocs:ref-first-fp>12</xocs:ref-first-fp><xocs:ref-last-lp>19</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0010"><xocs:ref-normalized-surname>PAAVONEN</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>2161</xocs:ref-first-fp><xocs:ref-last-lp>2170</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0015"><xocs:ref-normalized-surname>PAAVONEN</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>301</xocs:ref-first-fp><xocs:ref-last-lp>314</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0020"><xocs:ref-normalized-surname>ROMANOWSKI</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>1975</xocs:ref-first-fp><xocs:ref-last-lp>1985</xocs:ref-last-lp><xocs:ref-normalized-initial>B</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0025"><xocs:ref-normalized-surname>THEFUTUREIISTUDYGROUP</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>1915</xocs:ref-first-fp><xocs:ref-last-lp>1927</xocs:ref-last-lp></xocs:ref-info><xocs:ref-info refid="rf0030"><xocs:ref-normalized-surname>GARLAND</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>1928</xocs:ref-first-fp><xocs:ref-last-lp>1943</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0035"><xocs:ref-normalized-surname>MUNOZ</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>325</xocs:ref-first-fp><xocs:ref-last-lp>339</xocs:ref-last-lp><xocs:ref-normalized-initial>N</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0040"><xocs:ref-normalized-surname>MOTOYAMA</xocs:ref-normalized-surname><xocs:ref-pub-year>2004</xocs:ref-pub-year><xocs:ref-first-fp>9</xocs:ref-first-fp><xocs:ref-last-lp>19</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0045"><xocs:ref-normalized-surname>STANLEY</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>1456</xocs:ref-first-fp><xocs:ref-last-lp>1460</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0050"><xocs:ref-normalized-surname>HELLNER</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>1785</xocs:ref-first-fp><xocs:ref-last-lp>1794</xocs:ref-last-lp><xocs:ref-normalized-initial>K</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0055"><xocs:ref-normalized-surname>SU</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>109</xocs:ref-first-fp><xocs:ref-last-lp>129</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0060"><xocs:ref-normalized-surname>VANDERBURG</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>252</xocs:ref-first-fp><xocs:ref-last-lp>257</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0065"><xocs:ref-normalized-surname>LINDBLAD</xocs:ref-normalized-surname><xocs:ref-pub-year>2004</xocs:ref-pub-year><xocs:ref-first-fp>3658</xocs:ref-first-fp><xocs:ref-last-lp>3668</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0070"><xocs:ref-normalized-surname>LIN</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>4</xocs:ref-first-fp><xocs:ref-last-lp>24</xocs:ref-last-lp><xocs:ref-normalized-initial>K</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0075"><xocs:ref-normalized-surname>PASHINE</xocs:ref-normalized-surname><xocs:ref-pub-year>2005</xocs:ref-pub-year><xocs:ref-first-fp>S63</xocs:ref-first-fp><xocs:ref-last-lp>S68</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0080"><xocs:ref-normalized-surname>SINGH</xocs:ref-normalized-surname><xocs:ref-pub-year>1999</xocs:ref-pub-year><xocs:ref-first-fp>1075</xocs:ref-first-fp><xocs:ref-last-lp>1081</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0085"><xocs:ref-normalized-surname>OHAGAN</xocs:ref-normalized-surname><xocs:ref-pub-year>2004</xocs:ref-pub-year><xocs:ref-first-fp>259</xocs:ref-first-fp><xocs:ref-last-lp>270</xocs:ref-last-lp><xocs:ref-normalized-initial>D</xocs:ref-normalized-initial><xocs:ref-normalized-srctitle>NEWGENERATIONVACCINES</xocs:ref-normalized-srctitle><xocs:ref-normalized-article-title>RECENTDEVELOPMENTSINVACCINEDELIVERYSYSTEMS</xocs:ref-normalized-article-title></xocs:ref-info><xocs:ref-info refid="rf0090"><xocs:ref-normalized-surname>YUBA</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>943</xocs:ref-first-fp><xocs:ref-last-lp>951</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0095"><xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>832</xocs:ref-first-fp><xocs:ref-last-lp>841</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0100"><xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>654</xocs:ref-first-fp><xocs:ref-last-lp>660</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0105"><xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>e12279</xocs:ref-first-fp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0110"><xocs:ref-normalized-surname>BAUDNER</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>1477</xocs:ref-first-fp><xocs:ref-last-lp>1485</xocs:ref-last-lp><xocs:ref-normalized-initial>B</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0115"><xocs:ref-normalized-surname>SINGH</xocs:ref-normalized-surname><xocs:ref-pub-year>2001</xocs:ref-pub-year><xocs:ref-first-fp>1476</xocs:ref-first-fp><xocs:ref-last-lp>1479</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0120"><xocs:ref-normalized-surname>THOMANN</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>4574</xocs:ref-first-fp><xocs:ref-last-lp>4583</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0125"><xocs:ref-normalized-surname>COOPER</xocs:ref-normalized-surname><xocs:ref-pub-year>2004</xocs:ref-pub-year><xocs:ref-first-fp>693</xocs:ref-first-fp><xocs:ref-last-lp>701</xocs:ref-last-lp><xocs:ref-normalized-initial>C</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0130"><xocs:ref-normalized-surname>HALPERIN</xocs:ref-normalized-surname><xocs:ref-pub-year>2003</xocs:ref-pub-year><xocs:ref-first-fp>2461</xocs:ref-first-fp><xocs:ref-last-lp>2467</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0135"><xocs:ref-normalized-surname>KRIEG</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>1184</xocs:ref-first-fp><xocs:ref-last-lp>1194</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0140"><xocs:ref-normalized-surname>CHU</xocs:ref-normalized-surname><xocs:ref-pub-year>1997</xocs:ref-pub-year><xocs:ref-first-fp>1623</xocs:ref-first-fp><xocs:ref-last-lp>1631</xocs:ref-last-lp><xocs:ref-normalized-initial>R</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0145"><xocs:ref-normalized-surname>WEERATNA</xocs:ref-normalized-surname><xocs:ref-pub-year>2000</xocs:ref-pub-year><xocs:ref-first-fp>1755</xocs:ref-first-fp><xocs:ref-last-lp>1762</xocs:ref-last-lp><xocs:ref-normalized-initial>R</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0150"><xocs:ref-normalized-surname>ERIKCI</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>1715</xocs:ref-first-fp><xocs:ref-last-lp>1723</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0155"><xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>e40970</xocs:ref-first-fp><xocs:ref-normalized-initial>C</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0160"><xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>1856</xocs:ref-first-fp><xocs:ref-last-lp>1862</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0165"><xocs:ref-normalized-surname>AUCOUTURIER</xocs:ref-normalized-surname><xocs:ref-pub-year>2001</xocs:ref-pub-year><xocs:ref-first-fp>2666</xocs:ref-first-fp><xocs:ref-last-lp>2672</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0170"><xocs:ref-normalized-surname>REDDY</xocs:ref-normalized-surname><xocs:ref-pub-year>2006</xocs:ref-pub-year><xocs:ref-first-fp>573</xocs:ref-first-fp><xocs:ref-last-lp>579</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0175"><xocs:ref-normalized-surname>SEUBERT</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>11169</xocs:ref-first-fp><xocs:ref-last-lp>11174</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0180"><xocs:ref-normalized-surname>PARODI</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>93</xocs:ref-first-fp><xocs:ref-last-lp>106</xocs:ref-last-lp><xocs:ref-normalized-initial>V</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0185"><xocs:ref-normalized-surname>BEYER</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>5785</xocs:ref-first-fp><xocs:ref-last-lp>5792</xocs:ref-last-lp><xocs:ref-normalized-initial>W</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0190"><xocs:ref-normalized-surname>MOSCA</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>10501</xocs:ref-first-fp><xocs:ref-last-lp>10506</xocs:ref-last-lp><xocs:ref-normalized-initial>F</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0195"><xocs:ref-normalized-surname>ZHU</xocs:ref-normalized-surname><xocs:ref-pub-year>1995</xocs:ref-pub-year><xocs:ref-first-fp>557</xocs:ref-first-fp><xocs:ref-last-lp>563</xocs:ref-last-lp><xocs:ref-normalized-initial>X</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0200"><xocs:ref-normalized-surname>OHAGAN</xocs:ref-normalized-surname><xocs:ref-pub-year>2000</xocs:ref-pub-year><xocs:ref-first-fp>1793</xocs:ref-first-fp><xocs:ref-last-lp>1801</xocs:ref-last-lp><xocs:ref-normalized-initial>D</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0205"><xocs:ref-normalized-surname>HAILEMICHAEL</xocs:ref-normalized-surname><xocs:ref-pub-year>2013</xocs:ref-pub-year><xocs:ref-first-fp>465</xocs:ref-first-fp><xocs:ref-last-lp>472</xocs:ref-last-lp><xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0210"><xocs:ref-normalized-surname>KENTER</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>169</xocs:ref-first-fp><xocs:ref-last-lp>177</xocs:ref-last-lp><xocs:ref-normalized-initial>G</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0215"><xocs:ref-normalized-surname>KENTER</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>1838</xocs:ref-first-fp><xocs:ref-last-lp>1847</xocs:ref-last-lp><xocs:ref-normalized-initial>G</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0220"><xocs:ref-normalized-surname>MELIEF</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>300</xocs:ref-first-fp><xocs:ref-last-lp>301</xocs:ref-last-lp><xocs:ref-normalized-initial>C</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0225"><xocs:ref-normalized-surname>BEAUDETTE</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>1160</xocs:ref-first-fp><xocs:ref-last-lp>1169</xocs:ref-last-lp><xocs:ref-normalized-initial>T</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0230"><xocs:ref-normalized-surname>KAMMER</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>7065</xocs:ref-first-fp><xocs:ref-last-lp>7074</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0235"><xocs:ref-normalized-surname>CUI</xocs:ref-normalized-surname><xocs:ref-pub-year>2005</xocs:ref-pub-year><xocs:ref-first-fp>1180</xocs:ref-first-fp><xocs:ref-last-lp>1190</xocs:ref-last-lp><xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0240"><xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>517</xocs:ref-first-fp><xocs:ref-last-lp>530</xocs:ref-last-lp><xocs:ref-normalized-initial>W</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0245"><xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>464</xocs:ref-first-fp><xocs:ref-last-lp>471</xocs:ref-last-lp><xocs:ref-normalized-initial>W</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0250"><xocs:ref-normalized-surname>TOVEY</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>287</xocs:ref-first-fp><xocs:ref-last-lp>309</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0255"><xocs:ref-normalized-surname>LAPTEVA</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>725</xocs:ref-first-fp><xocs:ref-last-lp>733</xocs:ref-last-lp><xocs:ref-normalized-initial>N</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0260"><xocs:ref-normalized-surname>DUTHIE</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>178</xocs:ref-first-fp><xocs:ref-last-lp>196</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0265"><xocs:ref-normalized-surname>CELIS</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>7945</xocs:ref-first-fp><xocs:ref-last-lp>7947</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0340"><xocs:ref-normalized-surname>EVANS</xocs:ref-normalized-surname><xocs:ref-pub-year>2003</xocs:ref-pub-year><xocs:ref-first-fp>219</xocs:ref-first-fp><xocs:ref-last-lp>229</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0270"><xocs:ref-normalized-surname>STEINHAGEN</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>3341</xocs:ref-first-fp><xocs:ref-last-lp>3355</xocs:ref-last-lp><xocs:ref-normalized-initial>F</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0275"><xocs:ref-normalized-surname>STEERE</xocs:ref-normalized-surname><xocs:ref-pub-year>1998</xocs:ref-pub-year><xocs:ref-first-fp>209</xocs:ref-first-fp><xocs:ref-last-lp>215</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0280"><xocs:ref-normalized-surname>GARCON</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>4453</xocs:ref-first-fp><xocs:ref-last-lp>4459</xocs:ref-last-lp><xocs:ref-normalized-initial>N</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0285"><xocs:ref-normalized-surname>BURKE</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>147</xocs:ref-first-fp><xocs:ref-last-lp>156</xocs:ref-last-lp><xocs:ref-normalized-initial>B</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0290"><xocs:ref-normalized-surname>VERTHELYI</xocs:ref-normalized-surname><xocs:ref-pub-year>2004</xocs:ref-pub-year><xocs:ref-first-fp>1003</xocs:ref-first-fp><xocs:ref-last-lp>1008</xocs:ref-last-lp><xocs:ref-normalized-initial>D</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0295"><xocs:ref-normalized-surname>WEINER</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>263</xocs:ref-first-fp><xocs:ref-last-lp>267</xocs:ref-last-lp><xocs:ref-normalized-initial>G</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0300"><xocs:ref-normalized-surname>CARPENTIER</xocs:ref-normalized-surname><xocs:ref-pub-year>2006</xocs:ref-pub-year><xocs:ref-first-fp>60</xocs:ref-first-fp><xocs:ref-last-lp>66</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0305"><xocs:ref-normalized-surname>MUKHERJEE</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>1607</xocs:ref-first-fp><xocs:ref-last-lp>1618</xocs:ref-last-lp><xocs:ref-normalized-initial>P</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0310"><xocs:ref-normalized-surname>SEN</xocs:ref-normalized-surname><xocs:ref-pub-year>2006</xocs:ref-pub-year><xocs:ref-first-fp>2177</xocs:ref-first-fp><xocs:ref-last-lp>2186</xocs:ref-last-lp><xocs:ref-normalized-initial>G</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0315"><xocs:ref-normalized-surname>AMARAL</xocs:ref-normalized-surname><xocs:ref-pub-year>2005</xocs:ref-pub-year><xocs:ref-first-fp>325</xocs:ref-first-fp><xocs:ref-last-lp>333</xocs:ref-last-lp><xocs:ref-normalized-initial>C</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0320"><xocs:ref-normalized-surname>DAFTARIAN</xocs:ref-normalized-surname><xocs:ref-pub-year>2006</xocs:ref-pub-year><xocs:ref-first-fp>5235</xocs:ref-first-fp><xocs:ref-last-lp>5244</xocs:ref-last-lp><xocs:ref-normalized-initial>P</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0325"><xocs:ref-normalized-surname>CHANDY</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>6037</xocs:ref-first-fp><xocs:ref-last-lp>6046</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0330"><xocs:ref-normalized-surname>CERUTTI</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>1813</xocs:ref-first-fp><xocs:ref-last-lp>1820</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0335"><xocs:ref-normalized-surname>MANSILLA</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>641</xocs:ref-first-fp><xocs:ref-last-lp>651</xocs:ref-last-lp><xocs:ref-normalized-initial>C</xocs:ref-normalized-initial></xocs:ref-info></xocs:references><xocs:refkeys><xocs:refkey3>SONGX2014X158</xocs:refkey3><xocs:refkey4lp>SONGX2014X158X165</xocs:refkey4lp><xocs:refkey4ai>SONGX2014X158XY</xocs:refkey4ai><xocs:refkey5>SONGX2014X158X165XY</xocs:refkey5></xocs:refkeys><xocs:open-access><xocs:oa-article-status is-open-access="1" is-open-archive="0">Full</xocs:oa-article-status><xocs:oa-access-effective-date>2013-10-24T10:39:06Z</xocs:oa-access-effective-date><xocs:oa-sponsor><xocs:oa-sponsor-type>Author</xocs:oa-sponsor-type></xocs:oa-sponsor><xocs:oa-user-license>http://creativecommons.org/licenses/by-nc-sa/3.0/</xocs:oa-user-license></xocs:open-access><xocs:attachment-metadata-doc><xocs:attachment-set-type>item</xocs:attachment-set-type><xocs:pii-formatted>S0168-3659(13)00876-6</xocs:pii-formatted><xocs:pii-unformatted>S0168365913008766</xocs:pii-unformatted><xocs:eid>1-s2.0-S0168365913008766</xocs:eid><xocs:doi>10.1016/j.jconrel.2013.10.027</xocs:doi><xocs:cid>271103</xocs:cid><xocs:timestamp>2014-10-02T08:06:45.38509-04:00</xocs:timestamp><xocs:cover-date-start>2014-01-10</xocs:cover-date-start><xocs:sponsored-access-type>UNLIMITED</xocs:sponsored-access-type><xocs:funding-body-id>NONE</xocs:funding-body-id><xocs:attachments><xocs:web-pdf><xocs:attachment-eid>1-s2.0-S0168365913008766-main.pdf</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913008766/MAIN/application/pdf/1e9bbff85e865b81c41bd90877f99c2c/main.pdf</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913008766/MAIN/application/pdf/1e9bbff85e865b81c41bd90877f99c2c/main.pdf</xocs:ucs-locator><xocs:filename>main.pdf</xocs:filename><xocs:extension>pdf</xocs:extension><xocs:pdf-optimized>true</xocs:pdf-optimized><xocs:filesize>860805</xocs:filesize><xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose><xocs:web-pdf-page-count>8</xocs:web-pdf-page-count><xocs:web-pdf-images><xocs:web-pdf-image><xocs:attachment-eid>1-s2.0-S0168365913008766-main_1.png</xocs:attachment-eid><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913008766/PREVIEW/image/png/d686ba287b2b81c6407ecd9f485bca54/main_1.png</xocs:ucs-locator><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913008766/PREVIEW/image/png/d686ba287b2b81c6407ecd9f485bca54/main_1.png</xocs:ucs-locator><xocs:filename>main_1.png</xocs:filename><xocs:extension>png</xocs:extension><xocs:filesize>60502</xocs:filesize><xocs:pixel-height>849</xocs:pixel-height><xocs:pixel-width>656</xocs:pixel-width><xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type><xocs:pdf-page-num>1</xocs:pdf-page-num></xocs:web-pdf-image></xocs:web-pdf-images></xocs:web-pdf><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913008766-gr5_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913008766/gr5/HIGHRES/image/jpeg/d28ad7d7d9e979d897f4d3bb5f47a085/gr5_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913008766/gr5/HIGHRES/image/jpeg/d28ad7d7d9e979d897f4d3bb5f47a085/gr5_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr5</xocs:file-basename><xocs:filename>gr5_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>304840</xocs:filesize><xocs:pixel-height>1282</xocs:pixel-height><xocs:pixel-width>3030</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913008766-gr4_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913008766/gr4/HIGHRES/image/jpeg/e7db9ba74edf513a7e43e26de67cfaee/gr4_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913008766/gr4/HIGHRES/image/jpeg/e7db9ba74edf513a7e43e26de67cfaee/gr4_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>85981</xocs:filesize><xocs:pixel-height>855</xocs:pixel-height><xocs:pixel-width>1039</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913008766-gr3_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913008766/gr3/HIGHRES/image/jpeg/591cbac5f63ba673a7a598ff6b842ea8/gr3_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913008766/gr3/HIGHRES/image/jpeg/591cbac5f63ba673a7a598ff6b842ea8/gr3_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>283761</xocs:filesize><xocs:pixel-height>1941</xocs:pixel-height><xocs:pixel-width>1732</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913008766-gr2_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913008766/gr2/HIGHRES/image/jpeg/8cd2026be2da9e54b8198f4b22f3c47e/gr2_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913008766/gr2/HIGHRES/image/jpeg/8cd2026be2da9e54b8198f4b22f3c47e/gr2_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>549353</xocs:filesize><xocs:pixel-height>2659</xocs:pixel-height><xocs:pixel-width>1732</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913008766-gr1_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913008766/gr1/HIGHRES/image/jpeg/2eea88fc0fe63423e0ee693b0308342f/gr1_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913008766/gr1/HIGHRES/image/jpeg/2eea88fc0fe63423e0ee693b0308342f/gr1_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>672920</xocs:filesize><xocs:pixel-height>4401</xocs:pixel-height><xocs:pixel-width>1614</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913008766-fx1_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913008766/fx1/HIGHRES/image/jpeg/eb174f276726820cffd83ff5fc6e97c7/fx1_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913008766/fx1/HIGHRES/image/jpeg/eb174f276726820cffd83ff5fc6e97c7/fx1_lrg.jpg</xocs:ucs-locator><xocs:file-basename>fx1</xocs:file-basename><xocs:abstract-attachment>true</xocs:abstract-attachment><xocs:filename>fx1_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>250274</xocs:filesize><xocs:pixel-height>622</xocs:pixel-height><xocs:pixel-width>2213</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913008766-gr5.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913008766/gr5/DOWNSAMPLED/image/jpeg/a6f8a51c140f53e30eab26a843300c5e/gr5.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913008766/gr5/DOWNSAMPLED/image/jpeg/a6f8a51c140f53e30eab26a843300c5e/gr5.jpg</xocs:ucs-locator><xocs:file-basename>gr5</xocs:file-basename><xocs:filename>gr5.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>40473</xocs:filesize><xocs:pixel-height>289</xocs:pixel-height><xocs:pixel-width>684</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913008766-gr4.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913008766/gr4/DOWNSAMPLED/image/jpeg/3231f47dc04ef2f291c830ac761c177b/gr4.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913008766/gr4/DOWNSAMPLED/image/jpeg/3231f47dc04ef2f291c830ac761c177b/gr4.jpg</xocs:ucs-locator><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>29095</xocs:filesize><xocs:pixel-height>322</xocs:pixel-height><xocs:pixel-width>391</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913008766-gr3.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913008766/gr3/DOWNSAMPLED/image/jpeg/b382bca5e7d96fa48141a5a94a5d11eb/gr3.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913008766/gr3/DOWNSAMPLED/image/jpeg/b382bca5e7d96fa48141a5a94a5d11eb/gr3.jpg</xocs:ucs-locator><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>43078</xocs:filesize><xocs:pixel-height>438</xocs:pixel-height><xocs:pixel-width>391</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913008766-gr2.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913008766/gr2/DOWNSAMPLED/image/jpeg/9e948fec759d4dd1911a91321c1419b5/gr2.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913008766/gr2/DOWNSAMPLED/image/jpeg/9e948fec759d4dd1911a91321c1419b5/gr2.jpg</xocs:ucs-locator><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>68617</xocs:filesize><xocs:pixel-height>600</xocs:pixel-height><xocs:pixel-width>391</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913008766-gr1.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913008766/gr1/DOWNSAMPLED/image/jpeg/81435e770865950d20a90f0d953c6f69/gr1.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913008766/gr1/DOWNSAMPLED/image/jpeg/81435e770865950d20a90f0d953c6f69/gr1.jpg</xocs:ucs-locator><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>84367</xocs:filesize><xocs:pixel-height>993</xocs:pixel-height><xocs:pixel-width>364</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913008766-fx1.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913008766/fx1/DOWNSAMPLED/image/jpeg/25c5591f8b39ffc7c18300d67f469124/fx1.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913008766/fx1/DOWNSAMPLED/image/jpeg/25c5591f8b39ffc7c18300d67f469124/fx1.jpg</xocs:ucs-locator><xocs:file-basename>fx1</xocs:file-basename><xocs:abstract-attachment>true</xocs:abstract-attachment><xocs:filename>fx1.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>26285</xocs:filesize><xocs:pixel-height>141</xocs:pixel-height><xocs:pixel-width>500</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913008766-gr5.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913008766/gr5/THUMBNAIL/image/gif/5d8a8acb753fc461754f7192ddc01031/gr5.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913008766/gr5/THUMBNAIL/image/gif/5d8a8acb753fc461754f7192ddc01031/gr5.sml</xocs:ucs-locator><xocs:file-basename>gr5</xocs:file-basename><xocs:filename>gr5.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>3457</xocs:filesize><xocs:pixel-height>93</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913008766-gr4.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913008766/gr4/THUMBNAIL/image/gif/e1581c587322898b1e64b244d3abaca7/gr4.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913008766/gr4/THUMBNAIL/image/gif/e1581c587322898b1e64b244d3abaca7/gr4.sml</xocs:ucs-locator><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>3773</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>199</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913008766-gr3.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913008766/gr3/THUMBNAIL/image/gif/008e36b5c251af9701f5030a61a5cdfb/gr3.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913008766/gr3/THUMBNAIL/image/gif/008e36b5c251af9701f5030a61a5cdfb/gr3.sml</xocs:ucs-locator><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>3809</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>146</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913008766-gr2.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913008766/gr2/THUMBNAIL/image/gif/972ac8905f62031c9d2715f142437e37/gr2.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913008766/gr2/THUMBNAIL/image/gif/972ac8905f62031c9d2715f142437e37/gr2.sml</xocs:ucs-locator><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>6520</xocs:filesize><xocs:pixel-height>163</xocs:pixel-height><xocs:pixel-width>106</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913008766-gr1.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913008766/gr1/THUMBNAIL/image/gif/e5758a0d83607a2445cde269aaae5eb3/gr1.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913008766/gr1/THUMBNAIL/image/gif/e5758a0d83607a2445cde269aaae5eb3/gr1.sml</xocs:ucs-locator><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>2160</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>60</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913008766-fx1.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913008766/fx1/THUMBNAIL/image/gif/c51a70794fcdd2ccf6e0a98d34dd93a7/fx1.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913008766/fx1/THUMBNAIL/image/gif/c51a70794fcdd2ccf6e0a98d34dd93a7/fx1.sml</xocs:ucs-locator><xocs:file-basename>fx1</xocs:file-basename><xocs:abstract-attachment>true</xocs:abstract-attachment><xocs:filename>fx1.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>5730</xocs:filesize><xocs:pixel-height>62</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913008766-mmc1.pdf</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913008766/mmc1/MAIN/application/pdf/a43c158751de6a2a503836ee0ad30aa9/mmc1.pdf</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913008766/mmc1/MAIN/application/pdf/a43c158751de6a2a503836ee0ad30aa9/mmc1.pdf</xocs:ucs-locator><xocs:file-basename>mmc1</xocs:file-basename><xocs:filename>mmc1.pdf</xocs:filename><xocs:extension>pdf</xocs:extension><xocs:filesize>230680</xocs:filesize><xocs:attachment-type>APPLICATION</xocs:attachment-type></xocs:attachment></xocs:attachments></xocs:attachment-metadata-doc></xocs:meta><xocs:serial-item><article xmlns="http://www.elsevier.com/xml/ja/dtd" version="5.2" docsubtype="fla" xml:lang="en"><item-info><jid>COREL</jid><aid>6934</aid><ce:pii>S0168-3659(13)00876-6</ce:pii><ce:doi>10.1016/j.jconrel.2013.10.027</ce:doi><ce:copyright type="other" year="2013">The Authors</ce:copyright><ce:copyright-line>© 2013. Published by Elsevier B.V. All rights reserved.</ce:copyright-line></item-info><ce:floats><ce:figure id="f0010"><ce:label>Fig. 1</ce:label><ce:caption id="ca0005"><ce:simple-para id="sp0010" view="all">PELC-formulated peptide/protein vaccine. (A) The schematic representation of the PELC-formulated peptide/protein vaccine preparation. The preparation of PELC-adjuvanted peptide vaccine follows a two-step procedure that includes emulsification and dispersion. First, an aqueous solution containing PEG-<ce:italic>b</ce:italic>-PLACL and an oily phase consisting of squalene and Span®85 were homogenized to form a stable and isotropic emulsion, PELC. Next, the pre-emulsified stock was dispersed into a peptide/protein solution to form homogeneous nanoparticles in the second step. (B) Homogeneous fine particles were observed with an Olympus DP70 microscope and laser light scattering analysis. (C) Cumulative release of RAH peptide from the PELC formulation. RAH was formulated with or without 10% PELC (50<ce:hsp sp="0.25"/>μg per 50<ce:hsp sp="0.25"/>μl) and placed in a dialysis chamber in a eppendorf containing 1<ce:hsp sp="0.25"/>ml ddH<ce:inf loc="post">2</ce:inf>O. RAH release was monitored by the MicroBCA method. The data are presented as the mean<ce:hsp sp="0.25"/>+<ce:hsp sp="0.25"/>SD of four samples.</ce:simple-para></ce:caption><ce:link locator="gr1" id="lk0005"/></ce:figure><ce:figure id="f0015"><ce:label>Fig. 2</ce:label><ce:caption id="ca0010"><ce:simple-para id="sp0015" view="all">Release of PELC-formulated RAH-Alexa 647 <ce:italic>in vivo</ce:italic>. C57BL/6 mice were subcutaneously immunized with 50<ce:hsp sp="0.25"/>μg of RAH-Alexa 647 combined with CpG (10<ce:hsp sp="0.25"/>μg), PELC (10%) or both. (A) In-life fluorescence image was performed at different time course by using a Xenogen IVIS® Spectrum 200 Imaging System. (B) The fluorescent measurement and region of interest (ROI) were analyzed by using IVIS Living Image 4.0 software package. Data are expressed as the mean<ce:hsp sp="0.25"/>+<ce:hsp sp="0.25"/>SEM of three animals per group. *<ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05 <ce:italic>versus</ce:italic> RAH.</ce:simple-para></ce:caption><ce:link locator="gr2" id="lk0010"/></ce:figure><ce:figure id="f0020"><ce:label>Fig. 3</ce:label><ce:caption id="ca0015"><ce:simple-para id="sp0020" view="all">The RAH peptide formulated in PELC and CpG enhanced specific CD8<ce:sup loc="post">+</ce:sup> T cells. Mice were subcutaneously administered a single injection with PBS, RAH (10<ce:hsp sp="0.25"/>μg), RAH formulated in PELC (10%) (RAH/PELC), RAH admixed with CpG (10<ce:hsp sp="0.25"/>μg) (RAH/CpG), or RAH formulated in PELC and CpG (RAH/PELC/CpG). (A) After 7<ce:hsp sp="0.25"/>days, splenocytes were stained with a PE-conjugated RAH/MHC tetramer and FITC-labeled anti-CD8 antibody. The percentage of double-positive-staining cells relative to the total number of cells is indicated within each panel. In the down panel of A, the results are expressed as the mean<ce:hsp sp="0.25"/>+<ce:hsp sp="0.25"/>SEM of the percentage with double positive staining cells. (B) Splenocytes from immunized mice were stimulated with the RAH peptide (1<ce:hsp sp="0.25"/>μg) and examined for IFN-γ-secreting cells with ELISPOT. Data are expressed as the mean<ce:hsp sp="0.25"/>+<ce:hsp sp="0.25"/>SEM of four animals per group. *<ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/><ce:italic>0.05</ce:italic>, **<ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01, ***<ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.001.</ce:simple-para></ce:caption><ce:link locator="gr3" id="lk0015"/></ce:figure><ce:figure id="f0025"><ce:label>Fig. 4</ce:label><ce:caption id="ca0020"><ce:simple-para id="sp0025" view="all">The RAH peptide formulated in PELC and CpG elicited a cytotoxic T cell response <ce:italic>in vivo</ce:italic>. Naïve spleen cells were pulsed with or without 5<ce:hsp sp="0.25"/>μg/ml of RAH and then were stained with 10<ce:hsp sp="0.25"/>μM CFSE or 1<ce:hsp sp="0.25"/>μM of CFSE, respectively, for 15<ce:hsp sp="0.25"/>min at 37<ce:hsp sp="0.25"/>°C. Both types of CFSE-labeled cells were injected into vaccinated mice, and after 18<ce:hsp sp="0.25"/>h, the spleens were collected and analyzed by flow cytometry. The following equation was used to determine specific lysis: % Specific lysis<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>[(% non-peptide<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>A)<ce:hsp sp="0.25"/>−<ce:hsp sp="0.25"/>% RAH peptide]<ce:hsp sp="0.25"/>/<ce:hsp sp="0.25"/>(% non-peptide<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>A). The experiment was repeated twice. Adjustment factor (A)<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>RAH peptide/non-peptide from naïve controls. Data are expressed as the mean<ce:hsp sp="0.25"/>+<ce:hsp sp="0.25"/>SEM of four animals per group. ***<ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/><ce:italic>0.001</ce:italic>.</ce:simple-para></ce:caption><ce:link locator="gr4" id="lk0020"/></ce:figure><ce:figure id="f0030"><ce:label>Fig. 5</ce:label><ce:caption id="ca0025"><ce:simple-para id="sp0030" view="all">The RAH peptide formulated in PELC and CpG induced a large anti-tumor effect. TC-1 tumor-bearing mice (6 animals/group) received a single injection subcutaneously with PBS, RAH (10<ce:hsp sp="0.25"/>μg), RAH formulated in PELC (10%) (RAH/PELC), RAH admixed with CpG (10<ce:hsp sp="0.25"/>μg) (RAH/CpG), or RAH formulated in PELC and CpG (RAH/PELC/CpG). (A) The tumor volume is shown as length<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>width<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>width<ce:hsp sp="0.25"/>/<ce:hsp sp="0.25"/>2 (mm<ce:sup loc="post">3</ce:sup>). The data are expressed as the mean<ce:hsp sp="0.25"/>+<ce:hsp sp="0.25"/>SEM. (B) Tumor free survival rate was monitored over a 50-day post-tumor implantation period. Tumor-free mice were defined as having a non-enlarging mass<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>100<ce:hsp sp="0.25"/>mm<ce:sup loc="post">3</ce:sup> in volume.</ce:simple-para></ce:caption><ce:link locator="gr5" id="lk0025"/></ce:figure></ce:floats><head><ce:title id="ti0005">A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8<ce:sup loc="post">+</ce:sup> T-cell-mediated anti-tumor immunity</ce:title><ce:author-group id="ag0005"><ce:author id="au0005"><ce:given-name>Ying-Chyi</ce:given-name><ce:surname>Song</ce:surname><ce:cross-ref refid="af0005" id="cf0005"><ce:sup loc="post">a</ce:sup></ce:cross-ref></ce:author><ce:author id="au0010"><ce:given-name>Han-Yin</ce:given-name><ce:surname>Cheng</ce:surname><ce:cross-ref refid="af0005" id="cf0010"><ce:sup loc="post">a</ce:sup></ce:cross-ref></ce:author><ce:author id="au0015"><ce:given-name>Chih-Hsiang</ce:given-name><ce:surname>Leng</ce:surname><ce:cross-ref refid="af0005" id="cf0015"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="af0010" id="cf0020"><ce:sup loc="post">b</ce:sup></ce:cross-ref></ce:author><ce:author id="au0020"><ce:given-name>Sheng-Kuo</ce:given-name><ce:surname>Chiang</ce:surname><ce:cross-ref refid="af0005" id="cf0025"><ce:sup loc="post">a</ce:sup></ce:cross-ref></ce:author><ce:author id="au0025"><ce:given-name>Chih-Wei</ce:given-name><ce:surname>Lin</ce:surname><ce:cross-ref refid="af0005" id="cf0030"><ce:sup loc="post">a</ce:sup></ce:cross-ref></ce:author><ce:author id="au0030"><ce:given-name>Pele</ce:given-name><ce:surname>Chong</ce:surname><ce:cross-ref refid="af0005" id="cf0035"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="af0010" id="cf0040"><ce:sup loc="post">b</ce:sup></ce:cross-ref></ce:author><ce:author id="au0035" orcid="0000-0002-9670-3821"><ce:given-name>Ming-Hsi</ce:given-name><ce:surname>Huang</ce:surname><ce:cross-ref refid="af0005" id="cf0045"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="cr0005" id="cf0050"><ce:sup loc="post">⁎</ce:sup></ce:cross-ref><ce:e-address id="em0005" type="email">huangminghsi@nhri.org.tw</ce:e-address></ce:author><ce:author id="au0040"><ce:given-name>Shih-Jen</ce:given-name><ce:surname>Liu</ce:surname><ce:cross-ref refid="af0005" id="cf0055"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="af0010" id="cf0060"><ce:sup loc="post">b</ce:sup></ce:cross-ref><ce:cross-ref refid="cr0010" id="cf0065"><ce:sup loc="post">⁎⁎</ce:sup></ce:cross-ref><ce:e-address id="em0010" type="email">levent@nhri.org.tw</ce:e-address></ce:author><ce:affiliation id="af0005"><ce:label>a</ce:label><ce:textfn id="tn0005">National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan</ce:textfn><sa:affiliation><sa:organization>National Institute of Infectious Diseases and Vaccinology</sa:organization><sa:organization>National Health Research Institutes</sa:organization><sa:city>Miaoli</sa:city><sa:country>Taiwan</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id="af0010"><ce:label>b</ce:label><ce:textfn id="tn0010">Graduate Institute of Immunology, China Medical University, Taichung, Taiwan</ce:textfn><sa:affiliation><sa:organization>Graduate Institute of Immunology</sa:organization><sa:organization>China Medical University</sa:organization><sa:city>Taichung</sa:city><sa:country>Taiwan</sa:country></sa:affiliation></ce:affiliation><ce:correspondence id="cr0005"><ce:label>⁎</ce:label><ce:text id="tx0005">Corresponding author.</ce:text></ce:correspondence><ce:correspondence id="cr0010"><ce:label>⁎⁎</ce:label><ce:text id="tx0010">Correspondence to: S.-J. Liu, National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.</ce:text></ce:correspondence></ce:author-group><ce:date-received day="15" month="8" year="2013"/><ce:date-accepted day="21" month="10" year="2013"/><ce:abstract id="ab0005" view="all" class="author"><ce:section-title id="st0005">Abstract</ce:section-title><ce:abstract-sec id="as0005" view="all"><ce:simple-para id="sp0005" view="all">PELC is a novel emulsion-type adjuvant that contains the bioresorbable polymer poly (ethylene glycol)-block-poly (lactide-co-ε-caprolactone) (PEG-<ce:italic>b</ce:italic>-PLACL), Span®85 and squalene. To investigate whether PELC is able to enhance CTL responses of antigens for treating tumor, peptides or protein antigens derived from HPV16 E7 were formulated with PELC nanoparticles and CpG oligodeoxynucleotide. We identified that PELC formulation could delay the release of antigens <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic>. We assessed the immunogenicity of an H-2D<ce:sup loc="post">b</ce:sup>-restricted CTL epitope RAHYNIVTF (RAH) formulated with PELC or PELC/CpG and investigated the ability of these formulations to promote tumor regression. Following a single-dose subcutaneous injection in mice, we found that the RAH peptide formulated with PELC/CpG (RAH/PELC/CpG) resulted in increased numbers of IFN-γ-secreting cells and RAH-specific CD8<ce:sup loc="post">+</ce:sup> T cells and an enhanced cytotoxic T cell response compared with RAH formulated with PELC or CpG alone. The tumor-bearing mice received a single-dose injection of RAH/PELC/CpG, which induced complete tumor regression. These results demonstrated that peptide antigen formulated with PELC/CpG nanoparticles is feasible for cancer immunotherapy.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:abstract class="graphical" id="ab0010" view="all"><ce:section-title id="st0010">Graphical abstract</ce:section-title><ce:abstract-sec id="as0010" view="all"><ce:simple-para id="sp0040" view="all"><ce:display><ce:figure id="f0005"><ce:link locator="fx1" id="lk0030"/></ce:figure></ce:display></ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords id="ks0005" view="all" class="keyword"><ce:section-title id="st0015">Keywords</ce:section-title><ce:keyword id="kw0030"><ce:text id="tx0015">Adjuvant</ce:text></ce:keyword><ce:keyword id="kw0035"><ce:text id="tx0020">Immunotherapy</ce:text></ce:keyword><ce:keyword id="kw0040"><ce:text id="tx0025">Human papillomavirus (HPV)</ce:text></ce:keyword><ce:keyword id="kw0045"><ce:text id="tx0030">Cervical cancer</ce:text></ce:keyword><ce:keyword id="kw0050"><ce:text id="tx0035">CpG oligodeoxynucleotide</ce:text></ce:keyword></ce:keywords></head><body view="all"><ce:sections><ce:section id="s0005" view="all"><ce:label>1</ce:label><ce:section-title id="st0020">Introduction</ce:section-title><ce:para id="p0005" view="all">Human papillomavirus (HPV) infection is the most common cause of cervical cancer. Over 100 HPV types have been identified; some of the types that have been detected in cervical cancer are called “high-risk” HPV <ce:cross-ref refid="bb0005" id="cf0070">[1]</ce:cross-ref>. The four HPV types most frequently found among women worldwide with cervical cancer are types 16, 18, 33 and 58. Currently, there are two protein-based HPV vaccines (Cervarix® for types 16 and 18 and Gardasil® for types 6, 11, 16 and 18) used to prevent HPV infection and cervical intraepithelial neoplasia <ce:cross-refs refid="bb0010 bb0015 bb0020 bb0025 bb0030 bb0035" id="cf0075">[2–7]</ce:cross-refs>. Both vaccines contain the HPV capsid protein (L1), which can induce neutralizing antibodies that block virus infection but cannot destroy virally infected or cancer cells. However, the high cost of the HPV vaccines limits mass vaccination in developing countries. Therefore, the development of efficient therapeutic approaches for cervical cancer is still needed. The HPV E7 oncoprotein is highly conserved among different genotypes <ce:cross-refs refid="bb0040 bb0045" id="cf0080">[8,9]</ce:cross-refs>; moreover, it is a tumor-specific and a tumor-rejection antigen. Therefore, some studies have designed the E7 protein as the target for the development of therapeutic vaccines for treating HPV16-associated cancer and its precursor lesions <ce:cross-refs refid="bb0050 bb0055 bb0060" id="cf0085">[10–12]</ce:cross-refs>. In addition, the evolution of vaccine strategies has seen a move from whole organisms to recombinant proteins, with further development towards the most minimalist epitope possible. Nonetheless, a major challenge remains to turn poor immunogenic epitopes into potent and effective vaccines.</ce:para><ce:para id="p0010" view="all">In general, vaccines contain adjuvants to enhance the immunity against the immunogens and to thereby make the vaccine more effective. Aluminum-based mineral salts are currently incorporated as adjuvants in prophylactic HPV vaccines (Cervarix® and Gardasil®). These adjuvants effectively induce protective antibody titers against virus entry but do not induce Th1 responses or CTLs for killing HPV-infected or cervical cancer cells <ce:cross-ref refid="bb0065" id="cf0090">[13]</ce:cross-ref>. To this end, many new adjuvant formulations are being examined in various preclinical and clinical trials for treating cervical cancer <ce:cross-ref refid="bb0070" id="cf0095">[14]</ce:cross-ref>. On the basis of their mechanisms of action, adjuvants can be broadly divided into delivery systems and immunopotentiators <ce:cross-refs refid="bb0075 bb0080" id="cf0100">[15,16]</ce:cross-refs>. The delivery systems (for example, liposomes and MF59) may target antigens to the key cells and/or sites necessary to colocalize antigens and immunopotentiators <ce:cross-refs refid="bb0085 bb0090" id="cf0105">[17,18]</ce:cross-refs>. In our previous study, we introduced a new delivery system adjuvant (PELC) for the development of vaccines that was a water-in-oil-in-water nanoemulsion composed of a bioresorbable polymer, Span®85, and squalene <ce:cross-ref refid="bb0095" id="cf0110">[19]</ce:cross-ref>. In this emulsion, squalene was selected as the core oil, bioresorbable poly (ethylene glycol)-block-poly (lactide-co-ε-caprolactone) (PEG-<ce:italic>b</ce:italic>-PLACL) served as a hydrophilic emulsifier, and Span®85 acted as a hydrophobic emulsifier to stabilize the water/squalene interface. We also showed that a single-dose injection of the PELC nanoparticle-formulated inactivated H5N1 virus vaccine in mice induced potent antigen-specific antibody titers <ce:cross-ref refid="bb0100" id="cf0115">[20]</ce:cross-ref>. Moreover, emulsified PELC nanoparticles containing inactivated an H5N1 virus and CpG (an immunostimulatory oligodeoxynucleotide containing unmethylated cytosine–guanosine motifs) induced a cross-protecting antibody response against a heterologous virus strain <ce:cross-ref refid="bb0105" id="cf0120">[21]</ce:cross-ref>. However, whether the peptide/protein formulated with the PELC nanoparticle can induce cytotoxic T lymphocyte responses still needs to be investigated.</ce:para><ce:para id="p0015" view="all">Immunopotentiators activate innate immunity directly (for example, cytokines) or through pattern-recognition receptors (PRRs, such as those for bacterial components). The Toll-like receptors (TLRs) are a family of PRRs that are an important link between innate and adaptive immunity. Some studies have shown that TLR ligands have adjuvant activity and enhance antigen-specific antibody and cell-mediated immune responses, especially when they are combined with delivery systems that promote their uptake and delivery into antigen-presenting cells <ce:cross-refs refid="bb0110 bb0115 bb0120" id="cf0125">[22–24]</ce:cross-refs>. For clinical studies, TLR9 is generally stimulated with synthetic oligodeoxynucleotides containing one or more unmethylated CpG dinucleotides. In humans, CpG has been used as an adjuvant for infectious disease vaccination <ce:cross-refs refid="bb0125 bb0130" id="cf0130">[25,26]</ce:cross-refs> and in the development of cancer therapy <ce:cross-ref refid="bb0135" id="cf0135">[27]</ce:cross-ref>. In a mouse model, CpG has also been shown to induce T helper 1 (Th1) immune responses, which are characterized by the production of IFN-γ and the generation of IgG2a <ce:cross-refs refid="bb0140 bb0145" id="cf0140">[28,29]</ce:cross-refs>. Moreover, a previous study had demonstrated that different liposomes with CpG ODN significantly increased Th1-biased cytokines and augmented cell mediated immune response <ce:cross-ref refid="bb0150" id="cf0145">[30]</ce:cross-ref>.</ce:para><ce:para id="p0020" view="all">For this article, we selected an H-2D<ce:sup loc="post">b</ce:sup>-restricted CTL epitope (amino acids 49–57, RAHYNIVTF) (RAH) derived from the HPV 16 E7 protein or the recombinant mutant E7 (rE7m) <ce:cross-ref refid="bb0155" id="cf0150">[31]</ce:cross-ref> as models to study the cellular immune responses to the peptide/protein formulated with PELC or with a combination of PELC and CpG and to evaluate whether the candidate vaccine formulations could be used as a tool for cancer immunotherapy. We examined the cellular immune responses and the tumor regression in mice that received a single injection of RAH peptides alone or of RAH peptides formulated with PELC, CpG, or a PELC/CpG combination. This study demonstrated that peptide antigens formulated with both a delivery system (PELC) and an immunopotentiator (CpG) could induce strong CTL responses against cervical cancer.</ce:para></ce:section><ce:section id="s0010" view="all"><ce:label>2</ce:label><ce:section-title id="st0025">Materials and methods</ce:section-title><ce:section id="s0035" view="all"><ce:label>2.1</ce:label><ce:section-title id="st0060">Materials</ce:section-title><ce:para id="p0070" view="all">The H-2D<ce:sup loc="post">b</ce:sup>-restricted CTL epitope (amino acids 49–57, RAHYNIVTF) (RAH) derived from the HPV16 E7 protein was synthesized in-house by the solid phase method using an automated peptide synthesizer, model PS-3 from Protein Technologies, Inc. (Tucson, AZ, U.S.A.), employing the fluorenylmethoxycarbonyl (Fmoc) group for α-amino group protection. The final de-blocking step was carried out with Reagent K (a mixture of TFA/thioanisole/phenol/water/EDT). The crude peptide was recovered by a precipitation method with ether as the non-solvent and further purified by reversed-phase HPLC using a gradient elution. Mass spectrometry data were obtained from an Agilent 1100 Series LC/MSD high-performance ion trap mass spectrometer to ensure that purity higher than 90% was obtained. The peptide was dissolved in DMSO (Sigma, MO, USA) at a stock concentration of 10<ce:hsp sp="0.25"/>mg/ml. CpG ODN was synthesized by Invitrogen Taiwan Ltd. and given as a 10<ce:hsp sp="0.25"/>μg dose dissolved in PBS or in the antigenic media. The CpG ODN sequence used was 5′-TCC ATG ACG TTC CTG ACG TT-3′ with a phosphorothioate backbone. The TC-1 cell line, a mouse epithelial cell line transformed with the oncogenes Ras and HPV16 E6 and E7, was a kind gift from Dr. T-C. Wu (Johns Hopkins University, USA). TC-1 cells were cultured in DMEM (GIBCO-BRL, NY) supplemented with 10% heat-inactivated fetal bovine serum (HyClone, Logan, Utah), penicillin (100 U/ml) and streptomycin (100<ce:hsp sp="0.25"/>μg/ml) (GIBCO-BRL, NY, USA). A complete RPMI-10 medium contained RPMI-1640 supplemented with 10% (v/v) heat-inactivated fetal calf serum, 25<ce:hsp sp="0.25"/>mM HEPES (Biological industries, Beit Haemek, Israel), penicillin (100<ce:hsp sp="0.25"/>U/ml) and streptomycin (100<ce:hsp sp="0.25"/>μg/ml).</ce:para></ce:section><ce:section id="s0040" view="all"><ce:label>2.2</ce:label><ce:section-title id="st0065">The preparation of PELC</ce:section-title><ce:para id="p0075" view="all">PELC is a squalene nanoemulsion stabilized by Span®85 (sorbitan trioleate, Sigma-Aldrich, Steinheim, Germany) and PEG-<ce:italic>b</ce:italic>-PLACL, as previously described <ce:cross-refs refid="bb0095 bb0100 bb0160" id="cf0155">[19,20,32]</ce:cross-refs>. Briefly, 120<ce:hsp sp="0.25"/>mg of PEG-<ce:italic>b</ce:italic>-PLACL, 0.8<ce:hsp sp="0.25"/>ml of phosphate buffered saline (PBS), and 1.1<ce:hsp sp="0.25"/>ml of an oily solution consisting of squalene (Sigma-Aldrich, Steinheim, Germany) and Span®85 (85/15, v/v) were emulsified using a Polytron®PT 3100 homogenizer (Kinematica AG, Switzerland) at 6000<ce:hsp sp="0.25"/>rpm for 5<ce:hsp sp="0.25"/>min. The emulsified PELC formulation was stored at 4<ce:hsp sp="0.25"/>°C until use. A PELC-formulated vaccine was prepared for experiments by re-dispersing 200<ce:hsp sp="0.25"/>mL of a stock emulsion into 1800<ce:hsp sp="0.25"/>mL of a bulk vaccine and mixing with a test tube rotator (Labinco LD-79, Netherlands) at 5<ce:hsp sp="0.25"/>rpm at least 1<ce:hsp sp="0.25"/>h before injection. The microscopic aspects of the emulsions were monitoring with an optical microscope (Olympus DP70 Digital Microscope Camera, Melville, NY, USA). Particle size distribution was determined by the laser light scattering technique. Peptide release experiments were performed with the inverted dialysis tube method <ce:cross-ref refid="bb0165" id="cf0160">[33]</ce:cross-ref>. Briefly, RAH-containing formulations (50<ce:hsp sp="0.25"/>μg per 50<ce:hsp sp="0.25"/>μl) were first placed in a dialysis chamber (cut-off 0.2<ce:hsp sp="0.25"/>μm), and then the device was immersed in a 1.5<ce:hsp sp="0.25"/>ml eppedorf containing 1<ce:hsp sp="0.25"/>mL ddH<ce:inf loc="post">2</ce:inf>O and placed at 37<ce:hsp sp="0.25"/>°C. At different time intervals, the RAH release was regularly determined by the micro bicinchoninic acid (BCA) method (MicroBCA™ protein assay kit; Thermo, IL, USA).</ce:para></ce:section><ce:section id="s0045" view="all"><ce:label>2.3</ce:label><ce:section-title id="st0070"><ce:italic>In vivo</ce:italic> fluorescence imaging</ce:section-title><ce:para id="p0080" view="all">Alexa Fluor® 647-conjugated RAH peptide (RAH-Alexa 647, absorption<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>650<ce:hsp sp="0.25"/>nm; fluorescence emission<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>668<ce:hsp sp="0.25"/>nm) was purchased from GeneDireX (Nevada, USA). C57BL/6 mice were subcutaneously injected with 50<ce:hsp sp="0.25"/>μg of RAH-Alexa 647 combined with CpG (10<ce:hsp sp="0.25"/>μg), PELC (10%) or both. Before using Spectrum Imaging System, mice were anesthetized with isoflurane at a maintenance concentration of 2.5%, and oxygen pressurized at 4<ce:hsp sp="0.25"/>kg/cm<ce:sup loc="post">2</ce:sup> in conjunction with XGI-8 Anesthesia System. After treatment, in-life fluorescence analysis was performed at 6, 30, 48, 72, 144, 168, 240, 336 and 384<ce:hsp sp="0.25"/>h by using a Xenogen IVIS® Spectrum 200 Imaging System (Caliper Life Sciences, USA). The fluorescent measurement and region of interest (ROI) were quantified and analyzed by using IVIS Living Image 4.0 software package.</ce:para></ce:section><ce:section id="s0050" view="all"><ce:label>2.4</ce:label><ce:section-title id="st0075">Animals</ce:section-title><ce:para id="p0120" view="all">Female C57BL/6 mice, 6–12<ce:hsp sp="0.25"/>weeks of age, were obtained from the National Laboratory Animal Breeding and Research Center (Taipei, Taiwan). All the animals were housed at the Animal Center of National Health Research Institutes (NHRI) and maintained in accordance with the institutional animal care protocol. All of the animal studies were approved by the animal committee of the NHRI (NHRI-IACUC-095-051-A).</ce:para></ce:section><ce:section id="s0055" view="all"><ce:label>2.5</ce:label><ce:section-title id="st0080">The detection of peptide-specific CD8<ce:sup loc="post">+</ce:sup> T cells</ce:section-title><ce:para id="p0085" view="all">The C57BL/6 mice were immunized subcutaneously once with H-2D<ce:sup loc="post">b</ce:sup>-restricted CTL peptides (RAH; 10<ce:hsp sp="0.25"/>μg) mixed with or without 10<ce:hsp sp="0.25"/>μg of murine CpG ODN (Invitrogen) in PELC (10%) adjuvant. After one week, splenocytes were harvested, and the RAH-specific CD8<ce:sup loc="post">+</ce:sup> T cells were detected by tetramer staining using a PE-labeled RAH tetramer (Beckman Coulter, CA, USA) and a FITC-labeled anti-CD8 mAb (eBioscience, CA, USA). The stained RAH-specific CD8<ce:sup loc="post">+</ce:sup> T cells were analyzed by flow cytometry.</ce:para><ce:para id="p0025" view="all">For the ELISPOT assay, spleens from the immunized mice were harvested and the response of IFN-γ-secreting cells was determined by ELISPOT after 48<ce:hsp sp="0.25"/>h of peptide or protein re-stimulation. Briefly, 2<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">5</ce:sup> splenocytes were incubated with irrelevant peptides or RAH peptides in an anti-IFN-γ-coated PVDF plate for 48<ce:hsp sp="0.25"/>h. After the incubation, the cells were removed, and a biotinylated anti-IFN-γ antibody (eBioscience, San Diego, CA, USA) was added to each well. The plates were then incubated at 37<ce:hsp sp="0.25"/>°C for 2<ce:hsp sp="0.25"/>h. Following the addition of the avidin-HRP reagent (eBioscience, CA, USA), the assay was developed with a 3-amine-9-ethyl carbazole (AEC; Sigma-Aldrich, MO, USA) staining solution. The reaction was stopped after 4–6<ce:hsp sp="0.25"/>min by placing the plate under tap water. The spots were then counted using an ELISPOT reader (Cellular Technology Ltd., Shaker Heights, OH, USA).</ce:para></ce:section><ce:section id="s0060" view="all"><ce:label>2.6</ce:label><ce:section-title id="st0085"><ce:italic>In vivo</ce:italic> cytolysis assay</ce:section-title><ce:para id="p0090" view="all">The C57BL/6 mice were immunized subcutaneously once with RAH (10<ce:hsp sp="0.25"/>μg) mixed with or without 10<ce:hsp sp="0.25"/>μg of murine CpG ODN in a PELC (10%) adjuvant, and then after 7<ce:hsp sp="0.25"/>days, CFSE-labeled target cells were adoptively transferred into the mice. The target cells were prepared from syngeneic splenocytes treated with a RBC lysis buffer (Biolegend) for 2<ce:hsp sp="0.25"/>min to remove red blood cells. The cells were divided into two parts, one of which was pulsed with 5<ce:hsp sp="0.25"/>μg/ml of RAH peptides for 30<ce:hsp sp="0.25"/>min at 37<ce:hsp sp="0.25"/>°C. After the splenocytes were washed in PBS, the cells only (non-peptide) and RAH peptide-pulsed cells were labeled at final concentrations of 1<ce:hsp sp="0.25"/>μM CFSE (Molecular Probes, Eugene, OR) or 10<ce:hsp sp="0.25"/>μM CFSE, respectively, for 15<ce:hsp sp="0.25"/>min at 37<ce:hsp sp="0.25"/>°C. The splenocytes were added to an ice-cold complete RPMI medium to stop the CFSE labeling. The cells only and RAH-pulsed splenocytes were re-suspended in PBS and remixed at a ratio of 1:1. The CFSE-labeled cells (2<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">7</ce:sup> per mouse) were adoptively transferred <ce:italic>via</ce:italic> tail vein injection into the immunized mice. The experimental cells were harvested 18<ce:hsp sp="0.25"/>h after adoptive transfer and analyzed using FACSCalibur (Becton Dickinson Immunocytometry Systems, San Jose, CA). Two equations were used to determine the percentage of lysis. The adjustment factor (A) was calculated by dividing the percentage of cells loaded without peptide by the percentage of cells loaded with RAH peptide in naïve controls. For the percent lysis equation, the average of the As from 4 naïve mice was calculated, and the following equation was used: % Specific lysis<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>[(% non-peptide<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>A)<ce:hsp sp="0.25"/>−<ce:hsp sp="0.25"/>% RAH peptide]<ce:hsp sp="0.25"/>/<ce:hsp sp="0.25"/>(% non-peptide<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>A).</ce:para></ce:section><ce:section id="s0065" view="all"><ce:label>2.7</ce:label><ce:section-title id="st0090">Tumor regression study in mice</ce:section-title><ce:para id="p0095" view="all">To assess the therapeutic value of the vaccines, tumors were first generated by injecting 2<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">5</ce:sup> TC-1 cells into the abdominal region of the mice, and seven days later, the mice were subcutaneously vaccinated in a separate abdominal region with the indicated dose of vaccine formulated with PELC at 100<ce:hsp sp="0.25"/>μl/dose. The tumor volume and tumor free survival of the mice was monitored over a 50-day post-tumor implantation period.</ce:para></ce:section><ce:section id="s0070" view="all"><ce:label>2.8</ce:label><ce:section-title id="st0095">Statistical analysis</ce:section-title><ce:para id="p0100" view="all">The graphs and statistical analyses were performed using GraphPad Prism version 5.02 (GraphPad Software, Inc.). Multiple comparisons of the fluorescent measurement between groups and time points were calculated by using the ANOVA model followed by a Bonferroni posttest on log10-transformed values. Comparison of T cell immune responses between groups was determined by a multiple comparison test. The differences were considered significant at <ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05.</ce:para></ce:section></ce:section><ce:section id="s0015" view="all"><ce:label>3</ce:label><ce:section-title id="st0030">Results</ce:section-title><ce:section id="s0075" view="all"><ce:label>3.1</ce:label><ce:section-title id="st0100">The formulation of antigens with PELC</ce:section-title><ce:para id="p0105" view="all">The preparation of the PELC-formulated nanoparticle as an adjuvant follows a two-step manufacturing process, as shown in <ce:cross-ref refid="f0010" id="cf0165">Fig. 1</ce:cross-ref>A<ce:float-anchor refid="f0010"/>. In the first step, the aqueous solution of PEG-<ce:italic>b</ce:italic>-PLACL and the oil phase of squalene and Span®85 were pre-emulsified to form a stable and isotropic emulsion dubbed PELC. The aqueous solutions of antigen (RAH) and/or immunopotentiator (CpG) were mixed to form homogeneous particles in the second step. The size distribution of these particles was measured with a microscope and a particle size analyzer. Two different sizes were observed, relatively large particles of 1<ce:hsp sp="0.25"/>μm and smaller ones of 200<ce:hsp sp="0.25"/>nm (<ce:cross-ref refid="f0010" id="cf0170">Fig. 1</ce:cross-ref>B). Notably, several studies have verified that small solutes or nanoparticles (&lt;<ce:hsp sp="0.10"/>50<ce:hsp sp="0.25"/>nm) are internalized by antigen-presenting cells (APCs) through macropinocytosis <ce:cross-ref refid="bb0170" id="cf0175">[34]</ce:cross-ref>, whereas poly(lactide-co-glycolide) microparticles (&gt;<ce:hsp sp="0.10"/>500<ce:hsp sp="0.25"/>nm) and MF59 oil-in-water emulsion 200<ce:hsp sp="0.25"/>nm in size can be internalized APCs through phagocytosis without specific recognition <ce:cross-refs refid="bb0170 bb0175" id="cf0180">[34,35]</ce:cross-refs>. Here, PELC-formulated particles possess proper sizes for APCs uptake to facilitate the induction of cell-mediated immunity. To evaluate whether this type of formulation allows the antigen or immunopotentiator to be controlled and slowly released, an <ce:italic>in vitro</ce:italic> release experiment was performed using RAH as a model peptide. <ce:cross-ref refid="f0010" id="cf0185">Fig. 1</ce:cross-ref>C shows the cumulative release of RAH from the PELC formulation. In the case of RAH without an adjuvant, more than 90% of the loaded RAH was released into the aqueous solution within 48<ce:hsp sp="0.25"/>h. However, the release of the PELC-formulated RAH occurred with a significant delay, and less than 30% of the RAH was released during the same period of time (<ce:cross-ref refid="f0010" id="cf0190">Fig. 1</ce:cross-ref>C). These data showed that an aqueous solution of antigen, when formulated with PELC, forms homogeneous particles that delay the release of antigen. This delay may lessen the extent of degradation and, thereby, protect the antigen and facilitate its expression.</ce:para></ce:section><ce:section id="s0080" view="all"><ce:label>3.2</ce:label><ce:section-title id="st0105">PELC delay the release of antigen <ce:italic>in vivo</ce:italic></ce:section-title><ce:para id="p0030" view="all">To investigate the release rate of PELC-formulated peptide antigen <ce:italic>in vivo</ce:italic>, the mice were immunized with various formulations that contains RAH-Alexa 647 and in-life fluorescence analysis was performed at 0, 6, 30, 48, 72, 144, 168, 240, 336 and 384<ce:hsp sp="0.25"/>h. After the injection, the fluorescence signal was clearly presented on the dorsum of mice at 0<ce:hsp sp="0.25"/>h in each group. After 72<ce:hsp sp="0.25"/>h, the fluorescence signal dropped dramatically in both RAH-Alexa 647 alone (RAH group) and RAH-Alexa 647 mixed with CpG (RAH/CpG group) (<ce:cross-ref refid="f0015" id="cf0195">Fig. 2</ce:cross-ref>A<ce:float-anchor refid="f0015"/>). Data analysis from ROI showed us that the fluorescence signals had about a 75–80% decrement at 30<ce:hsp sp="0.25"/>h in the RAH and RAH/CpG groups (<ce:cross-ref refid="f0015" id="cf0200">Fig. 2</ce:cross-ref>B). On the other hand, the significant amount of fluorescence signals were still visible in the PELC formulated groups (RAH/PELC and RAH/CpG/PELC) at 240<ce:hsp sp="0.25"/>h (<ce:cross-ref refid="f0015" id="cf0205">Fig. 2</ce:cross-ref>A,B). Both <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> results demonstrated that the PELC emulsified delivery system could serve as either carrier or vehicle to deliver biologically active agents (<ce:italic>e.g.</ce:italic>, RAH peptide and CpG immunostimulatory adjuvants) to immune cells in a targeted and prolonged manner, thus effectively probing and manipulating the vaccine immunogenicity. These data were also confirmed in protein antigen (data not shown). Herein, PELC nanoemulsion has a depot effect that provides a sustained release profile of peptide/protein antigens.</ce:para></ce:section><ce:section id="s0020" view="all"><ce:label>3.3</ce:label><ce:section-title id="st0035">The RAH peptide formulated with PELC and/or CpG enhances specific CD8<ce:sup loc="post">+</ce:sup> T cells</ce:section-title><ce:para id="p0035" view="all">As we demonstrated that PELC nanoemulsion could prolong the release of antigens, we will identify the immune response of antigens after formulation with PELC and combination with or without CpG. The immunogenicity of the RAH peptide antigen after formulation with PELC, CpG or PELC/CpG was determined in the mice relative to the induction of the tumor antigen-specific CD8<ce:sup loc="post">+</ce:sup> T cell response. The RAH peptide was formulated with various emulsion formulae or PBS and injected subcutaneously into the C57BL/6 mice. After 7<ce:hsp sp="0.25"/>days, splenocytes were isolated from the immunized mice and re-stimulated <ce:italic>in vitro</ce:italic> in the presence of RAH. Among the various formulations, we found that RAH formulated with PELC/CpG (RAH/PELC/CpG) induced the highest number of RAH-specific CD8<ce:sup loc="post">+</ce:sup> T cells (0.32%) after immunization (<ce:cross-ref refid="f0020" id="cf0210">Fig. 3</ce:cross-ref>A<ce:float-anchor refid="f0020"/>). However, there was no significant induction of RAH-specific CD8<ce:sup loc="post">+</ce:sup> T cells in the immunization with the RAH peptide formulated with PELC or CpG alone compared to the RAH in PBS formulation (<ce:cross-ref refid="f0020" id="cf0215">Fig. 3</ce:cross-ref>A). To further investigate the RAH-specific IFN-γ-secreting cells after immunization, the splenocytes from vaccinated mice were re-stimulated with RAH. We found that the number of specific IFN-γ-secreting cells was increased by immunization with RAH/PELC/CpG compared with RAH, RAH/PELC or RAH/CpG (<ce:cross-ref refid="f0020" id="cf0220">Fig. 3</ce:cross-ref>B). Immunization with either RAH/PELC or RAH/CpG also resulted in slightly increased IFN-γ-secreting cells compared with RAH alone.</ce:para></ce:section><ce:section id="s0085" view="all"><ce:label>3.4</ce:label><ce:section-title id="st0110">The RAH peptide formulated with PELC and CpG elicits a CTL response</ce:section-title><ce:para id="p0110" view="all">We additionally sought to study the efficiency of different formulations for inducing a specific CTL response. To this end, the CTL responses were detected using the <ce:italic>in vivo</ce:italic> CTL assay. Briefly, the mice were immunized with RAH mixed with or without CpG in a PELC adjuvant. Seven days later, the immunized mice were adoptively transferred with CFSE-labeled target cells for 18<ce:hsp sp="0.25"/>h. The purpose of this assay is to evaluate whether immunized mice can kill peptide-pulsed cells specifically. Unvaccinated mice showed similar amounts of specific lysis as mice vaccinated with RAH peptides alone; RAH/PELC-immunized mice exhibited a mildly increased killing activity. In the presence of CpG ODN, the RAH peptide or RAH/PELC could induce strong cytotoxic effects (<ce:cross-ref refid="f0025" id="cf0225">Fig. 4</ce:cross-ref>A<ce:float-anchor refid="f0025"/>). The percentages of specific lysis were 0.52, 0.26, 0.90, 14.69, and 64.84% in the Control, RAH, RAH/PELC, RAH/CpG, and RAH/PELC/CpG groups, respectively (<ce:cross-ref refid="f0025" id="cf0230">Fig. 4</ce:cross-ref>B). This result indicates that the PELC adjuvant combined with CpG synergistically elicits a CTL response when used in a peptide vaccine.</ce:para></ce:section><ce:section id="s0090" view="all"><ce:label>3.5</ce:label><ce:section-title id="st0115">The RAH peptide formulated with PELC and/or CpG induces an anti-tumor effect</ce:section-title><ce:para id="p0040" view="extended">To determine whether the higher CTL response reflected anti-tumor activity <ce:italic>in vivo</ce:italic>, different RAH formulations were injected once 7<ce:hsp sp="0.25"/>days after tumor inoculation. We found that immunization with RAH/PELC or RAH/CpG delayed the tumor growth, but the tumor totally regressed in the group that had been immunized with RAH/PELC/CpG (<ce:cross-ref refid="f0030" id="cf0235">Fig. 5</ce:cross-ref>A<ce:float-anchor refid="f0030"/>). The mice in the PBS control or RAH alone groups all died before day 50 after tumor implantation. In contrast, the tumor-free survival rates were 30%, 50% and 100% for the RAH/PELC, RAH/CpG and RAH/PELC/CpG group, respectively (<ce:cross-ref refid="f0030" id="cf0240">Fig. 5</ce:cross-ref>B). To extend the application of this formulation, recombinant mutant E7 protein (rE7m) was formulated with PELC/CpG (rE7m/PELC/CpG) to immunize the mice once. Significant CD8<ce:sup loc="post">+</ce:sup> T cell response and tumor regression were observed after administering rE7m/PELC/CpG compared to rE7m/PELC or rE7m/CpG (<ce:cross-ref refid="ec0005" id="cf0245">Supplemental Fig. 1</ce:cross-ref>). Taken together, PELC combined with CpG adjuvant in a peptide/protein vaccine provides a robust CTL response and anti-tumor activity.</ce:para><ce:para id="p0042" view="compact-standard">To determine whether the higher CTL response reflected anti-tumor activity <ce:italic>in vivo</ce:italic>, different RAH formulations were injected once 7<ce:hsp sp="0.25"/>days after tumor inoculation. We found that immunization with RAH/PELC or RAH/CpG delayed the tumor growth, but the tumor totally regressed in the group that had been immunized with RAH/PELC/CpG (<ce:cross-ref refid="f0030" id="cf0237">Fig. 5</ce:cross-ref>A). The mice in the PBS control or RAH alone groups all died before day 50 after tumor implantation. In contrast, the tumor-free survival rates were 30%, 50% and 100% for the RAH/PELC, RAH/CpG and RAH/PELC/CpG group, respectively (<ce:cross-ref refid="f0030" id="cf0242">Fig. 5</ce:cross-ref>B). To extend the application of this formulation, recombinant mutant E7 protein (rE7m) was formulated with PELC/CpG (rE7m/PELC/CpG) to immunize the mice once. Significant CD8<ce:sup loc="post">+</ce:sup> T cell response and tumor regression were observed after administering rE7m/PELC/CpG compared to rE7m/PELC or rE7m/CpG (Supplemental Fig. 1). Taken together, PELC combined with CpG adjuvant in a peptide/protein vaccine provides a robust CTL response and anti-tumor activity.</ce:para></ce:section></ce:section><ce:section id="s0025" view="all"><ce:label>4</ce:label><ce:section-title id="st0040">Discussion</ce:section-title><ce:para id="p0045" view="all">The use of synthetic peptides and proteins as vaccines is safe, but because of poor immunogenicity, adjuvants are critical for inducing protective immunity. Based on their effective mechanisms, adjuvants can be divided into two types-antigen delivery systems and immunopotentiators. The induction of CTL responses using a peptide immunogen is not easy in the absence of adjuvants. To induce CTLs for killing cancer cells, the use of both an antigen delivery system and an immunopotentiator might generate synergistic effects. In the present study, we showed that using a synthetic peptide derived from HPV16 E7 or the recombinant mutant E7 (rE7m) as the immunogen could induce a significant anti-tumor effect in the presence of PELC and CpG. These new formulations could be potentially therapeutic vaccines for HPV-associated cancers.</ce:para><ce:section id="s0095" view="all"><ce:label>4.1</ce:label><ce:section-title id="st0120">The development of a W/O/W emulsion-type adjuvant (PELC) for cancer immunotherapy</ce:section-title><ce:para id="p0050" view="all">In theory, good antigen delivery systems are able to target antigen-presenting cells, such as dendritic cells, efficiently or prolong antigen presentation by preventing degradation. Antigen delivery systems include emulsion-type adjuvants and particulate-type adjuvants. An oil-in-water (O/W) emulsion-type adjuvant, MF59, has been used in flu vaccines, which has been shown to enhance antibody titers in an elderly population <ce:cross-refs refid="bb0180 bb0185" id="cf0250">[36,37]</ce:cross-refs>. MF59 has the advantages of low oil content and high injectability when performing vaccination. Regarding the mechanisms of adjuvant action, MF59 possesses high efficiency to the induction of an early and strong cytokine- and chemokine-rich environment at the site of injection, and the beneficial of modulation of genes involved in leukocyte migration and antigen presentation <ce:cross-ref refid="bb0190" id="cf0255">[38]</ce:cross-ref>. The E7 protein formulated in MF59 can generate CTL responses against E7-expressing cells, but the anti-tumor effect <ce:italic>in vivo</ce:italic> has not been reported <ce:cross-ref refid="bb0195" id="cf0260">[39]</ce:cross-ref>. In addition, the combination of polylactide co-glycolide polymer (PLG) microparticles and MF59 induced CTL activity against HIV-1 p24 gag <ce:cross-ref refid="bb0200" id="cf0265">[40]</ce:cross-ref>. However, further studies of MF59 as an adjuvant for cancer immunotherapy are limited. In contrast, the water-in-oil (W/O) emulsion-type adjuvant possesses dispersed antigenic media and continuous oily phases. This type of adjuvant has been evaluated to ascertain the innocuity of the vaccine and to achieve long-term protective immune responses. However, conventional incomplete Freund's adjuvant (IFA) causes extensive tissue inflammations at the injection site, so IFA is restricted for research purposes to laboratory animals. Unlike W/O/W adjuvant PELC, W/O adjuvant IFA generates long-lived depots in the injection site that may lead to the trapping of tumor-specific CD8<ce:hsp sp="0.10"/>+ T cells at the injection site instead of promoting an effective T cell response at the tumor site as described in the literature <ce:cross-ref refid="bb0205" id="cf0270">[41]</ce:cross-ref>. The new generation of W/O adjuvant, Montanide<ce:sup loc="post">TM</ce:sup> ISA51 and ISA 720, has been used in clinical studies of cancer immunotherapy. The long peptides (23–45 amino acids) of HPV16 E6 and E7 formulated with ISA-51 induced strong T cell responses in a phase I clinical trial <ce:cross-ref refid="bb0210" id="cf0275">[42]</ce:cross-ref>. In a further evaluation of the therapeutic efficacy of this formulation, HPV16-positive women with high-grade vulvar intraepithelial neoplasia were evaluated. Nine of twenty vaccinated patients showed complete regression of all lesions and eradication of the virus <ce:cross-refs refid="bb0215 bb0220" id="cf0280">[43,44]</ce:cross-refs>. These results showed that a peptide vaccine formulated with an emulsion-type adjuvant could generate strong T cell responses against an intraepithelial neoplasm. In the present study, PELC is a water-in-oil-in-water (W/O/W) emulsion-type adjuvant that is generally recognized as a more stable formulation <ce:cross-ref refid="bb0095" id="cf0285">[19]</ce:cross-ref>. It is probable that W/O/W not only reserved the depot effects intrinsic to W/O but also combined the antigen presentation effects belonging to O/W. Another advantage of the PELC formulation is that the pre-made emulsified PELC can simply be mixed with antigen before injection. This approach could reduce the potential for the incomplete emulsification of the vaccine because of the variability in individual compliance with procedures. Except for emulsion-type adjuvants, the peptides or proteins of HPV16 E7 have been incorporated into cationic liposomes, acid-degradable hydrogel particles <ce:cross-ref refid="bb0225" id="cf0290">[45]</ce:cross-ref> or virosomes <ce:cross-ref refid="bb0230" id="cf0295">[46]</ce:cross-ref> to treat established tumor models and have been shown to induce strong anti-tumor immunity <ce:cross-refs refid="bb0235 bb0240 bb0245" id="cf0300">[47–49]</ce:cross-refs>. These data demonstrated that an antigen delivery system adjuvant could be used to treat cancer. Here, our report showed that an easy-to-prepare PELC emulsion that was formulated with peptide enhanced the therapeutic effects of a cancer vaccine; in the presence of the TLR9 agonist (CpG) and PELC, the peptide formulation synergistically elicited anti-tumor immunity.</ce:para></ce:section><ce:section id="s0100" view="all"><ce:label>4.2</ce:label><ce:section-title id="st0125">The incorporation of a TLR ligand in the PELC formulation enhanced anti-tumor activity</ce:section-title><ce:para id="p0055" view="all">In addition to the delivery systems used in a vaccine adjuvant, the use of immunopotentiators as adjuvants also plays an important role in increasing the vaccine efficacy of immunogens, especially for peptides with poor immunogenicity. Immunopotentiators include cytokines (IL-2, GM-CSF) <ce:cross-ref refid="bb0250" id="cf0305">[50]</ce:cross-ref>, chemokines (CCL5) <ce:cross-ref refid="bb0255" id="cf0310">[51]</ce:cross-ref>, and innate receptor ligands (TLR2, TLR4 and TLR9) <ce:cross-refs refid="bb0260 bb0265 bb0270" id="cf0315">[52–54]</ce:cross-refs>. Because the innate receptors recognize conserved molecules expressed by a wide variety of infectious agents, using innate receptor ligands as adjuvants may mimic the natural infection of microbes. Currently, innate receptor ligands are recognized to be the new generation of adjuvants <ce:cross-ref refid="bb0275" id="cf0320">[55]</ce:cross-ref>. The TLR2 ligand, bacterial lipopeptide, has been used to manufacture a Lyme disease vaccine (LYMErix™) <ce:cross-ref refid="bb0280" id="cf0325">[56]</ce:cross-ref> and was licensed by the FDA in 1998 for general use. The monophosphoryl lipid A (MPL) is a TLR4 ligand that has been combined with aluminum salt (known as AS04) for hepatitis B vaccine (FENDrix®) or HPV vaccine (Cervarix®) <ce:cross-ref refid="bb0285" id="cf0330">[57]</ce:cross-ref>. Most recently, the unmethylated CpG motif in bacterial DNA has been identified as a TLR9 ligand that stimulates endosomal TLR9 in antigen-presenting cells (<ce:italic>i.e.</ce:italic>, DC or macrophage). The synthetic oligodeoxynucleotide (ODN) contains unmethylated cytosine–guanosine motifs (CpG) that are usually composed of a phosphorothioate nucleotide. The preclinical studies indicated that CpG has a good safety profile and improves the activity of vaccines targeting infectious diseases and cancer <ce:cross-refs refid="bb0290 bb0295 bb0300 bb0305 bb0310 bb0315 bb0320" id="cf0335">[58–64]</ce:cross-refs>. The Pan-DR Th epitope has been conjugated to a peptide of HPV16 E7 and formulated in a liposome and ISA-51 (called VacciMax®) with CpG and was shown to eradicate established tumors <ce:italic>in vivo</ce:italic> <ce:cross-ref refid="bb0325" id="cf0340">[65]</ce:cross-ref>. The combination therapy with cholera toxin-E7 fusion protein-pulsed DCs and the local treatment of the tumor with CpG was required for the complete eradication of cancer <ce:cross-ref refid="bb0330" id="cf0345">[66]</ce:cross-ref>. A new, low-dose, chemically stabilized form of the E7SOs (E7SOx) that has been combined with CpG as an adjuvant elicits a strong long-lasting protection against E7-expressed cancer <ce:cross-ref refid="bb0335" id="cf0350">[67]</ce:cross-ref>. Mansilla et al. reported that intravenous injection with the extracellular domain of fibronectin fused with E7, in combination with the TLR3 ligand, polyinosinic–polycytidylic acid (pIC), or CpG complexed with cationic lipids, was able to eradicate large established TC-1 tumors <ce:cross-ref refid="bb0340" id="cf0355">[68]</ce:cross-ref>. These promising results indicate that immunopotentiator CpG could be very useful as an adjuvant in cervical cancer immunotherapy.</ce:para></ce:section></ce:section><ce:section id="s0030" view="all"><ce:label>5</ce:label><ce:section-title id="st0045">Conclusion</ce:section-title><ce:para id="p0060" view="all">Our work presented here demonstrated that immunization of the mice with the RAH peptide formulated with PELC or CpG alone induced specific CD8<ce:sup loc="post">+</ce:sup> T cell responses and an anti-tumor effect. However, immunization with RAH/PELC mildly influenced the killing activity, presumably due to the difference in the induction times of the CD8<ce:sup loc="post">+</ce:sup> T cell responses between immunization with RAH/PELC and RAH/CpG. Moreover, PELC-formulated peptide vaccine in the presence of CpG synergistically elicited a CTL response and inhibited tumor growth. This formulation may attenuate peptide degradation to protect the antigen and increase the half-life of the antigen. Taken together, we found that a peptide/protein antigen formulated with the novel emulsion-type adjuvant combined with an immune potentiator (TLR9 ligand) could induce strong CTL responses against cancer. The combination of an antigen delivery system and immunopotentiators is a superb strategy for the development of therapeutic tumor vaccines.</ce:para><ce:para view="extended" id="p0115">The following are the supplementary data related to this article.<ce:display><ce:e-component id="ec0005"><ce:label>Supplemental Fig. 1</ce:label><ce:caption id="ca0030"><ce:simple-para id="sp0035" view="all">rE7m antigen formulated in PELC and CpG enhanced high CD8 T cell immunity and anti-tumor effect. Mice were subcutaneously administered with PBS, rE7m (30<ce:hsp sp="0.25"/>μg), rE7m formulated in PELC (10%) (rE7m/PELC), rE7m admixed in CpG (10<ce:hsp sp="0.25"/>μg) (rE7m/CpG), or rE7m formulated in PELC and CpG (rE7m/PELC/CpG). After two weeks, splenocytes were stimulated with the rE7m (10<ce:hsp sp="0.25"/>μg) for 5<ce:hsp sp="0.25"/>days and the levels of (A) IFN-γ and (B) IL-10 in the culture supernatant were measured by ELISA. Data are expressed as means<ce:hsp sp="0.25"/>+<ce:hsp sp="0.25"/>SEM of two animals per group. (C) Splenocytes from immunized mice were stimulated with the rE7m (10<ce:hsp sp="0.25"/>μg) and examined for IFN-γ-secreting cells by ELISPOTs. Data are expressed as means<ce:hsp sp="0.25"/>+<ce:hsp sp="0.25"/>SEM of three animals per group. **<ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01. (D) TC-1 tumor-bearing mice (6 animals/group) received a single injection with PBS, rE7m, rE7m/PELC, rE7m/CpG, or rE7m/PELC/CpG. The tumor diameters are shown (mm3). Data are expressed as means<ce:hsp sp="0.25"/>+<ce:hsp sp="0.25"/>SEM.</ce:simple-para></ce:caption><ce:link locator="mmc1"/></ce:e-component></ce:display></ce:para><ce:para view="compact-standard" id="p0125">Supplementary data to this article can be found online at <ce:inter-ref xlink:href="doi:10.1016/j.jconrel.2013.10.027" id="ir0005" xlink:type="simple">http://dx.doi.org/10.1016/j.jconrel.2013.10.027</ce:inter-ref>.</ce:para></ce:section></ce:sections><ce:acknowledgment id="ac0005" view="all"><ce:section-title id="st0050">Acknowledgments</ce:section-title><ce:para id="p0065" view="all">This study was supported by grants from the <ce:grant-sponsor id="gts0005" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">National Health Research Institutes</ce:grant-sponsor> (<ce:grant-number refid="gts0005">VC-100-PP-04</ce:grant-number> to S.-J. Liu and <ce:grant-number refid="gts0005">VC-100-PP-05</ce:grant-number> to M.-H. Huang). The authors thank T-C- Wu at Johns Hopkins University for the TC-1 cells.</ce:para></ce:acknowledgment></body><tail view="all"><ce:bibliography id="bi0005" view="all"><ce:section-title id="st0055">References</ce:section-title><ce:bibliography-sec id="bs0005" view="all"><ce:bib-reference id="bb0005"><ce:label>[1]</ce:label><sb:reference id="rf0005"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.M.</ce:given-name><ce:surname>Walboomers</ce:surname></sb:author><sb:author><ce:given-name>M.V.</ce:given-name><ce:surname>Jacobs</ce:surname></sb:author><sb:author><ce:given-name>M.M.</ce:given-name><ce:surname>Manos</ce:surname></sb:author><sb:author><ce:given-name>F.X.</ce:given-name><ce:surname>Bosch</ce:surname></sb:author><sb:author><ce:given-name>J.A.</ce:given-name><ce:surname>Kummer</ce:surname></sb:author><sb:author><ce:given-name>K.V.</ce:given-name><ce:surname>Shah</ce:surname></sb:author><sb:author><ce:given-name>P.J.</ce:given-name><ce:surname>Snijders</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Peto</ce:surname></sb:author><sb:author><ce:given-name>C.J.</ce:given-name><ce:surname>Meijer</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Munoz</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Human papilloma virus is a necessary cause of invasive cervical cancer worldwide</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Pathol.</sb:maintitle></sb:title><sb:volume-nr>189</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>12</sb:first-page><sb:last-page>19</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0010"><ce:label>[2]</ce:label><sb:reference id="rf0010"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Paavonen</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Jenkins</ce:surname></sb:author><sb:author><ce:given-name>F.X.</ce:given-name><ce:surname>Bosch</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Naud</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Salmeron</ce:surname></sb:author><sb:author><ce:given-name>C.M.</ce:given-name><ce:surname>Wheeler</ce:surname></sb:author><sb:author><ce:given-name>S.N.</ce:given-name><ce:surname>Chow</ce:surname></sb:author><sb:author><ce:given-name>D.L.</ce:given-name><ce:surname>Apter</ce:surname></sb:author><sb:author><ce:given-name>H.C.</ce:given-name><ce:surname>Kitchener</ce:surname></sb:author><sb:author><ce:given-name>X.</ce:given-name><ce:surname>Castellsague</ce:surname></sb:author><sb:author><ce:given-name>N.S.</ce:given-name><ce:surname>de Carvalho</ce:surname></sb:author><sb:author><ce:given-name>S.R.</ce:given-name><ce:surname>Skinner</ce:surname></sb:author><sb:author><ce:given-name>D.M.</ce:given-name><ce:surname>Harper</ce:surname></sb:author><sb:author><ce:given-name>J.A.</ce:given-name><ce:surname>Hedrick</ce:surname></sb:author><sb:author><ce:given-name>U.</ce:given-name><ce:surname>Jaisamrarn</ce:surname></sb:author><sb:author><ce:given-name>G.A.</ce:given-name><ce:surname>Limson</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Dionne</ce:surname></sb:author><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Quint</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Spiessens</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Peeters</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Struyf</ce:surname></sb:author><sb:author><ce:given-name>S.L.</ce:given-name><ce:surname>Wieting</ce:surname></sb:author><sb:author><ce:given-name>M.O.</ce:given-name><ce:surname>Lehtinen</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Dubin</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Lancet</sb:maintitle></sb:title><sb:volume-nr>369</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>2161</sb:first-page><sb:last-page>2170</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0015"><ce:label>[3]</ce:label><sb:reference id="rf0015"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Paavonen</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Naud</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Salmeron</ce:surname></sb:author><sb:author><ce:given-name>C.M.</ce:given-name><ce:surname>Wheeler</ce:surname></sb:author><sb:author><ce:given-name>S.N.</ce:given-name><ce:surname>Chow</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Apter</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Kitchener</ce:surname></sb:author><sb:author><ce:given-name>X.</ce:given-name><ce:surname>Castellsague</ce:surname></sb:author><sb:author><ce:given-name>J.C.</ce:given-name><ce:surname>Teixeira</ce:surname></sb:author><sb:author><ce:given-name>S.R.</ce:given-name><ce:surname>Skinner</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Hedrick</ce:surname></sb:author><sb:author><ce:given-name>U.</ce:given-name><ce:surname>Jaisamrarn</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Limson</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Garland</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Szarewski</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Romanowski</ce:surname></sb:author><sb:author><ce:given-name>F.Y.</ce:given-name><ce:surname>Aoki</ce:surname></sb:author><sb:author><ce:given-name>T.F.</ce:given-name><ce:surname>Schwarz</ce:surname></sb:author><sb:author><ce:given-name>W.A.</ce:given-name><ce:surname>Poppe</ce:surname></sb:author><sb:author><ce:given-name>F.X.</ce:given-name><ce:surname>Bosch</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Jenkins</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Hardt</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Zahaf</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Descamps</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Struyf</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Lehtinen</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Dubin</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Lancet</sb:maintitle></sb:title><sb:volume-nr>374</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>301</sb:first-page><sb:last-page>314</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0020"><ce:label>[4]</ce:label><sb:reference id="rf0020"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Romanowski</ce:surname></sb:author><sb:author><ce:given-name>P.C.</ce:given-name><ce:surname>de Borba</ce:surname></sb:author><sb:author><ce:given-name>P.S.</ce:given-name><ce:surname>Naud</ce:surname></sb:author><sb:author><ce:given-name>C.M.</ce:given-name><ce:surname>Roteli-Martins</ce:surname></sb:author><sb:author><ce:given-name>N.S.</ce:given-name><ce:surname>De Carvalho</ce:surname></sb:author><sb:author><ce:given-name>J.C.</ce:given-name><ce:surname>Teixeira</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Aoki</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Ramjattan</ce:surname></sb:author><sb:author><ce:given-name>R.M.</ce:given-name><ce:surname>Shier</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Somani</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Barbier</ce:surname></sb:author><sb:author><ce:given-name>M.M.</ce:given-name><ce:surname>Blatter</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Chambers</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Ferris</ce:surname></sb:author><sb:author><ce:given-name>S.A.</ce:given-name><ce:surname>Gall</ce:surname></sb:author><sb:author><ce:given-name>F.A.</ce:given-name><ce:surname>Guerra</ce:surname></sb:author><sb:author><ce:given-name>D.M.</ce:given-name><ce:surname>Harper</ce:surname></sb:author><sb:author><ce:given-name>J.A.</ce:given-name><ce:surname>Hedrick</ce:surname></sb:author><sb:author><ce:given-name>D.C.</ce:given-name><ce:surname>Henry</ce:surname></sb:author><sb:author><ce:given-name>A.P.</ce:given-name><ce:surname>Korn</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Kroll</ce:surname></sb:author><sb:author><ce:given-name>A.B.</ce:given-name><ce:surname>Moscicki</ce:surname></sb:author><sb:author><ce:given-name>W.D.</ce:given-name><ce:surname>Rosenfeld</ce:surname></sb:author><sb:author><ce:given-name>B.J.</ce:given-name><ce:surname>Sullivan</ce:surname></sb:author><sb:author><ce:given-name>C.S.</ce:given-name><ce:surname>Thoming</ce:surname></sb:author><sb:author><ce:given-name>S.K.</ce:given-name><ce:surname>Tyring</ce:surname></sb:author><sb:author><ce:given-name>C.M.</ce:given-name><ce:surname>Wheeler</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Dubin</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Schuind</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Zahaf</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Greenacre</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Sgriobhadair</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4<ce:hsp sp="0.25"/>years</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Lancet</sb:maintitle></sb:title><sb:volume-nr>374</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>1975</sb:first-page><sb:last-page>1985</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0025"><ce:label>[5]</ce:label><sb:reference id="rf0025"><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>The FUTURE II Study Group</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>N. Engl. J. Med.</sb:maintitle></sb:title><sb:volume-nr>356</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>1915</sb:first-page><sb:last-page>1927</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0030"><ce:label>[6]</ce:label><sb:reference id="rf0030"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.M.</ce:given-name><ce:surname>Garland</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Hernandez-Avila</ce:surname></sb:author><sb:author><ce:given-name>C.M.</ce:given-name><ce:surname>Wheeler</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Perez</ce:surname></sb:author><sb:author><ce:given-name>D.M.</ce:given-name><ce:surname>Harper</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Leodolter</ce:surname></sb:author><sb:author><ce:given-name>G.W.</ce:given-name><ce:surname>Tang</ce:surname></sb:author><sb:author><ce:given-name>D.G.</ce:given-name><ce:surname>Ferris</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Steben</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Bryan</ce:surname></sb:author><sb:author><ce:given-name>F.J.</ce:given-name><ce:surname>Taddeo</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Railkar</ce:surname></sb:author><sb:author><ce:given-name>M.T.</ce:given-name><ce:surname>Esser</ce:surname></sb:author><sb:author><ce:given-name>H.L.</ce:given-name><ce:surname>Sings</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Nelson</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Boslego</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Sattler</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Barr</ce:surname></sb:author><sb:author><ce:given-name>L.A.</ce:given-name><ce:surname>Koutsky</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>N. Engl. J. Med.</sb:maintitle></sb:title><sb:volume-nr>356</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>1928</sb:first-page><sb:last-page>1943</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0035"><ce:label>[7]</ce:label><sb:reference id="rf0035"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Munoz</ce:surname></sb:author><sb:author><ce:given-name>S.K.</ce:given-name><ce:surname>Kjaer</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Sigurdsson</ce:surname></sb:author><sb:author><ce:given-name>O.E.</ce:given-name><ce:surname>Iversen</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Hernandez-Avila</ce:surname></sb:author><sb:author><ce:given-name>C.M.</ce:given-name><ce:surname>Wheeler</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Perez</ce:surname></sb:author><sb:author><ce:given-name>D.R.</ce:given-name><ce:surname>Brown</ce:surname></sb:author><sb:author><ce:given-name>L.A.</ce:given-name><ce:surname>Koutsky</ce:surname></sb:author><sb:author><ce:given-name>E.H.</ce:given-name><ce:surname>Tay</ce:surname></sb:author><sb:author><ce:given-name>P.J.</ce:given-name><ce:surname>Garcia</ce:surname></sb:author><sb:author><ce:given-name>K.A.</ce:given-name><ce:surname>Ault</ce:surname></sb:author><sb:author><ce:given-name>S.M.</ce:given-name><ce:surname>Garland</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Leodolter</ce:surname></sb:author><sb:author><ce:given-name>S.E.</ce:given-name><ce:surname>Olsson</ce:surname></sb:author><sb:author><ce:given-name>G.W.</ce:given-name><ce:surname>Tang</ce:surname></sb:author><sb:author><ce:given-name>D.G.</ce:given-name><ce:surname>Ferris</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Paavonen</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Steben</ce:surname></sb:author><sb:author><ce:given-name>F.X.</ce:given-name><ce:surname>Bosch</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Dillner</ce:surname></sb:author><sb:author><ce:given-name>W.K.</ce:given-name><ce:surname>Huh</ce:surname></sb:author><sb:author><ce:given-name>E.A.</ce:given-name><ce:surname>Joura</ce:surname></sb:author><sb:author><ce:given-name>R.J.</ce:given-name><ce:surname>Kurman</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Majewski</ce:surname></sb:author><sb:author><ce:given-name>E.R.</ce:given-name><ce:surname>Myers</ce:surname></sb:author><sb:author><ce:given-name>L.L.</ce:given-name><ce:surname>Villa</ce:surname></sb:author><sb:author><ce:given-name>F.J.</ce:given-name><ce:surname>Taddeo</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Roberts</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Tadesse</ce:surname></sb:author><sb:author><ce:given-name>J.T.</ce:given-name><ce:surname>Bryan</ce:surname></sb:author><sb:author><ce:given-name>L.C.</ce:given-name><ce:surname>Lupinacci</ce:surname></sb:author><sb:author><ce:given-name>K.E.</ce:given-name><ce:surname>Giacoletti</ce:surname></sb:author><sb:author><ce:given-name>H.L.</ce:given-name><ce:surname>Sings</ce:surname></sb:author><sb:author><ce:given-name>M.K.</ce:given-name><ce:surname>James</ce:surname></sb:author><sb:author><ce:given-name>T.M.</ce:given-name><ce:surname>Hesley</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Barr</ce:surname></sb:author><sb:author><ce:given-name>R.M.</ce:given-name><ce:surname>Haupt</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Natl. Cancer Inst.</sb:maintitle></sb:title><sb:volume-nr>102</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>325</sb:first-page><sb:last-page>339</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0040"><ce:label>[8]</ce:label><sb:reference id="rf0040"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Motoyama</ce:surname></sb:author><sb:author><ce:given-name>C.A.</ce:given-name><ce:surname>Ladines-Llave</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Luis Villanueva</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Maruo</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The role of human papilloma virus in the molecular biology of cervical carcinogenesis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Kobe J. Med. Sci.</sb:maintitle></sb:title><sb:volume-nr>50</sb:volume-nr></sb:series><sb:date>2004</sb:date></sb:issue><sb:pages><sb:first-page>9</sb:first-page><sb:last-page>19</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0045"><ce:label>[9]</ce:label><sb:reference id="rf0045"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.A.</ce:given-name><ce:surname>Stanley</ce:surname></sb:author><sb:author><ce:given-name>M.R.</ce:given-name><ce:surname>Pett</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Coleman</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>HPV: from infection to cancer</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biochem. Soc. Trans.</sb:maintitle></sb:title><sb:volume-nr>35</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>1456</sb:first-page><sb:last-page>1460</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0050"><ce:label>[10]</ce:label><sb:reference id="rf0050"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Hellner</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Munger</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Human papillomaviruses as therapeutic targets in human cancer</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Clin. Oncol.</sb:maintitle></sb:title><sb:volume-nr>29</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>1785</sb:first-page><sb:last-page>1794</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0055"><ce:label>[11]</ce:label><sb:reference id="rf0055"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.H.</ce:given-name><ce:surname>Su</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Wu</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Scotney</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Ma</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Monie</ce:surname></sb:author><sb:author><ce:given-name>C.F.</ce:given-name><ce:surname>Hung</ce:surname></sb:author><sb:author><ce:given-name>T.C.</ce:given-name><ce:surname>Wu</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Immunotherapy for cervical cancer: research status and clinical potential</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>BioDrugs</sb:maintitle></sb:title><sb:volume-nr>24</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>109</sb:first-page><sb:last-page>129</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0060"><ce:label>[12]</ce:label><sb:reference id="rf0060"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.H.</ce:given-name><ce:surname>van der Burg</ce:surname></sb:author><sb:author><ce:given-name>C.J.</ce:given-name><ce:surname>Melief</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Therapeutic vaccination against human papilloma virus induced malignancies</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Curr. Opin. Immunol.</sb:maintitle></sb:title><sb:volume-nr>23</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>252</sb:first-page><sb:last-page>257</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0065"><ce:label>[13]</ce:label><sb:reference id="rf0065"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.B.</ce:given-name><ce:surname>Lindblad</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Aluminium adjuvants — in retrospect and prospect</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Vaccine</sb:maintitle></sb:title><sb:volume-nr>22</sb:volume-nr></sb:series><sb:date>2004</sb:date></sb:issue><sb:pages><sb:first-page>3658</sb:first-page><sb:last-page>3668</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0070"><ce:label>[14]</ce:label><sb:reference id="rf0070"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Lin</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Doolan</ce:surname></sb:author><sb:author><ce:given-name>C.F.</ce:given-name><ce:surname>Hung</ce:surname></sb:author><sb:author><ce:given-name>T.C.</ce:given-name><ce:surname>Wu</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Perspectives for preventive and therapeutic HPV vaccines</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Formos. Med. Assoc.</sb:maintitle></sb:title><sb:volume-nr>109</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>4</sb:first-page><sb:last-page>24</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0075"><ce:label>[15]</ce:label><sb:reference id="rf0075"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Pashine</ce:surname></sb:author><sb:author><ce:given-name>N.M.</ce:given-name><ce:surname>Valiante</ce:surname></sb:author><sb:author><ce:given-name>J.B.</ce:given-name><ce:surname>Ulmer</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Targeting the innate immune response with improved vaccine adjuvants</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nat. Med.</sb:maintitle></sb:title><sb:volume-nr>11</sb:volume-nr></sb:series><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>S63</sb:first-page><sb:last-page>S68</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0080"><ce:label>[16]</ce:label><sb:reference id="rf0080"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Singh</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>O'Hagan</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Advances in vaccine adjuvants</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nat. Biotechnol.</sb:maintitle></sb:title><sb:volume-nr>17</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>1075</sb:first-page><sb:last-page>1081</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0085"><ce:label>[17]</ce:label><sb:reference id="rf0085"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>D.T.</ce:given-name><ce:surname>O'Hagan</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Recent developments in vaccine delivery systems</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:editors><sb:editor><ce:given-name>M.M.</ce:given-name><ce:surname>Levine</ce:surname></sb:editor><sb:editor><ce:given-name>J.B.</ce:given-name><ce:surname>Kaper</ce:surname></sb:editor><sb:editor><ce:given-name>R.</ce:given-name><ce:surname>Rappuoli</ce:surname></sb:editor><sb:editor><ce:given-name>M.</ce:given-name><ce:surname>Liu</ce:surname></sb:editor><sb:editor><ce:given-name>M.F.</ce:given-name><ce:surname>Good</ce:surname></sb:editor></sb:editors><sb:title><sb:maintitle>New Generation Vaccines</sb:maintitle></sb:title><sb:edition>3th ed.</sb:edition><sb:date>2004</sb:date><sb:publisher><sb:name>Marcel Dekker Inc.</sb:name><sb:location>New York</sb:location></sb:publisher></sb:edited-book><sb:pages><sb:first-page>259</sb:first-page><sb:last-page>270</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0090"><ce:label>[18]</ce:label><sb:reference id="rf0090"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Yuba</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Kojima</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Harada</ce:surname></sb:author><sb:author><ce:surname>Tana</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Watarai</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Kono</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>pH-Sensitive fusogenic polymer-modified liposomes as a carrier of antigenic proteins for activation of cellular immunity</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biomaterials</sb:maintitle></sb:title><sb:volume-nr>31</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>943</sb:first-page><sb:last-page>951</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0095"><ce:label>[19]</ce:label><sb:reference id="rf0095"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.H.</ce:given-name><ce:surname>Huang</ce:surname></sb:author><sb:author><ce:given-name>A.H.</ce:given-name><ce:surname>Chou</ce:surname></sb:author><sb:author><ce:given-name>S.P.</ce:given-name><ce:surname>Lien</ce:surname></sb:author><sb:author><ce:given-name>H.W.</ce:given-name><ce:surname>Chen</ce:surname></sb:author><sb:author><ce:given-name>C.Y.</ce:given-name><ce:surname>Huang</ce:surname></sb:author><sb:author><ce:given-name>W.W.</ce:given-name><ce:surname>Chen</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Chong</ce:surname></sb:author><sb:author><ce:given-name>S.J.</ce:given-name><ce:surname>Liu</ce:surname></sb:author><sb:author><ce:given-name>C.H.</ce:given-name><ce:surname>Leng</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Formulation and immunological evaluation of novel vaccine delivery systems based on bioresorbable poly (ethylene glycol)-block-poly (lactide-co-epsilon-caprolactone)</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Biomed. Mater. Res. B Appl. Biomater.</sb:maintitle></sb:title><sb:volume-nr>90</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>832</sb:first-page><sb:last-page>841</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0100"><ce:label>[20]</ce:label><sb:reference id="rf0100"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.H.</ce:given-name><ce:surname>Huang</ce:surname></sb:author><sb:author><ce:given-name>C.Y.</ce:given-name><ce:surname>Huang</ce:surname></sb:author><sb:author><ce:given-name>S.C.</ce:given-name><ce:surname>Lin</ce:surname></sb:author><sb:author><ce:given-name>J.H.</ce:given-name><ce:surname>Chen</ce:surname></sb:author><sb:author><ce:given-name>C.C.</ce:given-name><ce:surname>Ku</ce:surname></sb:author><sb:author><ce:given-name>A.H.</ce:given-name><ce:surname>Chou</ce:surname></sb:author><sb:author><ce:given-name>S.J.</ce:given-name><ce:surname>Liu</ce:surname></sb:author><sb:author><ce:given-name>H.W.</ce:given-name><ce:surname>Chen</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Chong</ce:surname></sb:author><sb:author><ce:given-name>C.H.</ce:given-name><ce:surname>Leng</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Enhancement of potent antibody and T-cell responses by a single-dose, novel nanoemulsion-formulated pandemic influenza vaccine</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Microbes Infect.</sb:maintitle></sb:title><sb:volume-nr>11</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>654</sb:first-page><sb:last-page>660</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0105"><ce:label>[21]</ce:label><sb:reference id="rf0105"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.H.</ce:given-name><ce:surname>Huang</ce:surname></sb:author><sb:author><ce:given-name>S.C.</ce:given-name><ce:surname>Lin</ce:surname></sb:author><sb:author><ce:given-name>C.H.</ce:given-name><ce:surname>Hsiao</ce:surname></sb:author><sb:author><ce:given-name>H.J.</ce:given-name><ce:surname>Chao</ce:surname></sb:author><sb:author><ce:given-name>H.R.</ce:given-name><ce:surname>Yang</ce:surname></sb:author><sb:author><ce:given-name>C.C.</ce:given-name><ce:surname>Liao</ce:surname></sb:author><sb:author><ce:given-name>P.W.</ce:given-name><ce:surname>Chuang</ce:surname></sb:author><sb:author><ce:given-name>H.P.</ce:given-name><ce:surname>Wu</ce:surname></sb:author><sb:author><ce:given-name>C.Y.</ce:given-name><ce:surname>Huang</ce:surname></sb:author><sb:author><ce:given-name>C.H.</ce:given-name><ce:surname>Leng</ce:surname></sb:author><sb:author><ce:given-name>S.J.</ce:given-name><ce:surname>Liu</ce:surname></sb:author><sb:author><ce:given-name>H.W.</ce:given-name><ce:surname>Chen</ce:surname></sb:author><sb:author><ce:given-name>A.H.</ce:given-name><ce:surname>Chou</ce:surname></sb:author><sb:author><ce:given-name>A.Y.</ce:given-name><ce:surname>Hu</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Chong</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>PLoS One</sb:maintitle></sb:title><sb:volume-nr>5</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>e12279</sb:first-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0110"><ce:label>[22]</ce:label><sb:reference id="rf0110"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>B.C.</ce:given-name><ce:surname>Baudner</ce:surname></sb:author><sb:author><ce:given-name>V.</ce:given-name><ce:surname>Ronconi</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Casini</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Tortoli</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Kazzaz</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Singh</ce:surname></sb:author><sb:author><ce:given-name>L.D.</ce:given-name><ce:surname>Hawkins</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Wack</ce:surname></sb:author><sb:author><ce:given-name>D.T.</ce:given-name><ce:surname>O'Hagan</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020)</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Pharm. Res.</sb:maintitle></sb:title><sb:volume-nr>26</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>1477</sb:first-page><sb:last-page>1485</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0115"><ce:label>[23]</ce:label><sb:reference id="rf0115"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Singh</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Ott</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Kazzaz</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Ugozzoli</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Briones</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Donnelly</ce:surname></sb:author><sb:author><ce:given-name>D.T.</ce:given-name><ce:surname>O'Hagan</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Cationic microparticles are an effective delivery system for immune stimulatory cpG DNA</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Pharm. Res.</sb:maintitle></sb:title><sb:volume-nr>18</sb:volume-nr></sb:series><sb:date>2001</sb:date></sb:issue><sb:pages><sb:first-page>1476</sb:first-page><sb:last-page>1479</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0120"><ce:label>[24]</ce:label><sb:reference id="rf0120"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.S.</ce:given-name><ce:surname>Thomann</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Heurtault</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Weidner</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Brayé</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Beyrath</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Fournel</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Schuber</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Frisch</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biomaterials</sb:maintitle></sb:title><sb:volume-nr>32</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>4574</sb:first-page><sb:last-page>4583</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0125"><ce:label>[25]</ce:label><sb:reference id="rf0125"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>C.L.</ce:given-name><ce:surname>Cooper</ce:surname></sb:author><sb:author><ce:given-name>H.L.</ce:given-name><ce:surname>Davis</ce:surname></sb:author><sb:author><ce:given-name>M.L.</ce:given-name><ce:surname>Morris</ce:surname></sb:author><sb:author><ce:given-name>S.M.</ce:given-name><ce:surname>Efler</ce:surname></sb:author><sb:author><ce:given-name>M.A.</ce:given-name><ce:surname>Adhami</ce:surname></sb:author><sb:author><ce:given-name>A.M.</ce:given-name><ce:surname>Krieg</ce:surname></sb:author><sb:author><ce:given-name>D.W.</ce:given-name><ce:surname>Cameron</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Heathcote</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Clin. Immunol.</sb:maintitle></sb:title><sb:volume-nr>24</sb:volume-nr></sb:series><sb:date>2004</sb:date></sb:issue><sb:pages><sb:first-page>693</sb:first-page><sb:last-page>701</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0130"><ce:label>[26]</ce:label><sb:reference id="rf0130"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.A.</ce:given-name><ce:surname>Halperin</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Van Nest</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Smith</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Abtahi</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Whiley</ce:surname></sb:author><sb:author><ce:given-name>J.J.</ce:given-name><ce:surname>Eiden</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Vaccine</sb:maintitle></sb:title><sb:volume-nr>21</sb:volume-nr></sb:series><sb:date>2003</sb:date></sb:issue><sb:pages><sb:first-page>2461</sb:first-page><sb:last-page>2467</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0135"><ce:label>[27]</ce:label><sb:reference id="rf0135"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.M.</ce:given-name><ce:surname>Krieg</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Development of TLR9 agonists for cancer therapy</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Clin. Invest.</sb:maintitle></sb:title><sb:volume-nr>117</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>1184</sb:first-page><sb:last-page>1194</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0140"><ce:label>[28]</ce:label><sb:reference id="rf0140"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>R.S.</ce:given-name><ce:surname>Chu</ce:surname></sb:author><sb:author><ce:given-name>O.S.</ce:given-name><ce:surname>Targoni</ce:surname></sb:author><sb:author><ce:given-name>A.M.</ce:given-name><ce:surname>Krieg</ce:surname></sb:author><sb:author><ce:given-name>P.V.</ce:given-name><ce:surname>Lehmann</ce:surname></sb:author><sb:author><ce:given-name>C.V.</ce:given-name><ce:surname>Harding</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Exp. Med.</sb:maintitle></sb:title><sb:volume-nr>186</sb:volume-nr></sb:series><sb:date>1997</sb:date></sb:issue><sb:pages><sb:first-page>1623</sb:first-page><sb:last-page>1631</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0145"><ce:label>[29]</ce:label><sb:reference id="rf0145"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>R.D.</ce:given-name><ce:surname>Weeratna</ce:surname></sb:author><sb:author><ce:given-name>M.J.</ce:given-name><ce:surname>McCluskie</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Xu</ce:surname></sb:author><sb:author><ce:given-name>H.L.</ce:given-name><ce:surname>Davis</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>CpG DNA induces stronger immune responses with less toxicity than other adjuvants</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Vaccine</sb:maintitle></sb:title><sb:volume-nr>18</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>1755</sb:first-page><sb:last-page>1762</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0150"><ce:label>[30]</ce:label><sb:reference id="rf0150"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Erikci</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Gursel</ce:surname></sb:author><sb:author><ce:given-name>I.</ce:given-name><ce:surname>Gursel</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Differential immune activation following encapsulation of immunostimulatory CpG oligodeoxynucleotide in nanoliposomes</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biomaterials</sb:maintitle></sb:title><sb:volume-nr>32</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>1715</sb:first-page><sb:last-page>1723</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0155"><ce:label>[31]</ce:label><sb:reference id="rf0155"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>C.Y.</ce:given-name><ce:surname>Huang</ce:surname></sb:author><sb:author><ce:given-name>J.J.</ce:given-name><ce:surname>Chen</ce:surname></sb:author><sb:author><ce:given-name>K.Y.</ce:given-name><ce:surname>Shen</ce:surname></sb:author><sb:author><ce:given-name>L.S.</ce:given-name><ce:surname>Chang</ce:surname></sb:author><sb:author><ce:given-name>Y.C.</ce:given-name><ce:surname>Yeh</ce:surname></sb:author><sb:author><ce:given-name>I.H.</ce:given-name><ce:surname>Chen</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Chong</ce:surname></sb:author><sb:author><ce:given-name>S.J.</ce:given-name><ce:surname>Liu</ce:surname></sb:author><sb:author><ce:given-name>C.H.</ce:given-name><ce:surname>Leng</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Recombinant lipidated HPV E7 induces a Th-1-biased immune response and protective immunity against cervical cancer in a mouse model</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>PLoS One</sb:maintitle></sb:title><sb:volume-nr>7</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>e40970</sb:first-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0160"><ce:label>[32]</ce:label><sb:reference id="rf0160"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.H.</ce:given-name><ce:surname>Huang</ce:surname></sb:author><sb:author><ce:given-name>C.Y.</ce:given-name><ce:surname>Huang</ce:surname></sb:author><sb:author><ce:given-name>S.P.</ce:given-name><ce:surname>Lien</ce:surname></sb:author><sb:author><ce:given-name>S.Y.</ce:given-name><ce:surname>Siao</ce:surname></sb:author><sb:author><ce:given-name>A.H.</ce:given-name><ce:surname>Chou</ce:surname></sb:author><sb:author><ce:given-name>H.W.</ce:given-name><ce:surname>Chen</ce:surname></sb:author><sb:author><ce:given-name>C.H.</ce:given-name><ce:surname>Leng</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Chong</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Development of multi-phase emulsions based on bioresorbable polymers and oily adjuvant</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Pharm. Res.</sb:maintitle></sb:title><sb:volume-nr>26</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>1856</sb:first-page><sb:last-page>1862</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0165"><ce:label>[33]</ce:label><sb:reference id="rf0165"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Aucouturier</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Dupuis</ce:surname></sb:author><sb:author><ce:given-name>V.</ce:given-name><ce:surname>Ganne</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Adjuvants designed for veterinary and human vaccines</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Vaccine</sb:maintitle></sb:title><sb:volume-nr>19</sb:volume-nr></sb:series><sb:date>2001</sb:date></sb:issue><sb:pages><sb:first-page>2666</sb:first-page><sb:last-page>2672</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0170"><ce:label>[34]</ce:label><sb:reference id="rf0170"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.T.</ce:given-name><ce:surname>Reddy</ce:surname></sb:author><sb:author><ce:given-name>M.A.</ce:given-name><ce:surname>Swartz</ce:surname></sb:author><sb:author><ce:given-name>J.A.</ce:given-name><ce:surname>Hubbell</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Targeting dendritic cells with biomaterials: developing the next generation of vaccines</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Trends Immunol.</sb:maintitle></sb:title><sb:volume-nr>27</sb:volume-nr></sb:series><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>573</sb:first-page><sb:last-page>579</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0175"><ce:label>[35]</ce:label><sb:reference id="rf0175"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Seubert</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Calabro</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Santini</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Galli</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Genovese</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Valentini</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Aprea</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Colaprico</ce:surname></sb:author><sb:author><ce:given-name>U.</ce:given-name><ce:surname>D'Oro</ce:surname></sb:author><sb:author><ce:given-name>M.M.</ce:given-name><ce:surname>Giuliani</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Pallaoro</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Pizza</ce:surname></sb:author><sb:author><ce:given-name>D.T.</ce:given-name><ce:surname>O'Hagan</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Wack</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Rappuoli</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>De Gregorio</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle></sb:title><sb:volume-nr>108</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>11169</sb:first-page><sb:last-page>11174</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0180"><ce:label>[36]</ce:label><sb:reference id="rf0180"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>V.</ce:given-name><ce:surname>Parodi</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>de Florentiis</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Martini</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Ansaldi</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Inactivated influenza vaccines: recent progress and implications for the elderly</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Drugs Aging</sb:maintitle></sb:title><sb:volume-nr>28</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>93</sb:first-page><sb:last-page>106</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0185"><ce:label>[37]</ce:label><sb:reference id="rf0185"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>W.E.</ce:given-name><ce:surname>Beyer</ce:surname></sb:author><sb:author><ce:given-name>J.J.</ce:given-name><ce:surname>Nauta</ce:surname></sb:author><sb:author><ce:given-name>A.M.</ce:given-name><ce:surname>Palache</ce:surname></sb:author><sb:author><ce:given-name>K.M.</ce:given-name><ce:surname>Giezeman</ce:surname></sb:author><sb:author><ce:given-name>A.D.</ce:given-name><ce:surname>Osterhaus</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Vaccine</sb:maintitle></sb:title><sb:volume-nr>29</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>5785</sb:first-page><sb:last-page>5792</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0190"><ce:label>[38]</ce:label><sb:reference id="rf0190"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Mosca</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Tritto</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Muzzi</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Monaci</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Bagnoli</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Iavarone</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>O'Hagan</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Rappuoli</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>De Gregorio</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Molecular and cellular signatures of human vaccine adjuvants</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle></sb:title><sb:volume-nr>105</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>10501</sb:first-page><sb:last-page>10506</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0195"><ce:label>[39]</ce:label><sb:reference id="rf0195"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>X.</ce:given-name><ce:surname>Zhu</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Tommasino</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Vousden</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Sadovnikava</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Rappuoli</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Crawford</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Kast</ce:surname></sb:author><sb:author><ce:given-name>C.J.</ce:given-name><ce:surname>Melief</ce:surname></sb:author><sb:author><ce:given-name>P.C.</ce:given-name><ce:surname>Beverley</ce:surname></sb:author><sb:author><ce:given-name>H.J.</ce:given-name><ce:surname>Stauss</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papilloma virus 16 in H-2d mice</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Scand. J. Immunol.</sb:maintitle></sb:title><sb:volume-nr>42</sb:volume-nr></sb:series><sb:date>1995</sb:date></sb:issue><sb:pages><sb:first-page>557</sb:first-page><sb:last-page>563</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0200"><ce:label>[40]</ce:label><sb:reference id="rf0200"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>D.T.</ce:given-name><ce:surname>O'Hagan</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Ugozzoli</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Barackman</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Singh</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Kazzaz</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Higgins</ce:surname></sb:author><sb:author><ce:given-name>T.C.</ce:given-name><ce:surname>Vancott</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Ott</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Vaccine</sb:maintitle></sb:title><sb:volume-nr>18</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>1793</sb:first-page><sb:last-page>1801</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0205"><ce:label>[41]</ce:label><sb:reference id="rf0205"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Hailemichael</ce:surname></sb:author><sb:author><ce:given-name>Z.</ce:given-name><ce:surname>Dai</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Jaffarzad</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Ye</ce:surname></sb:author><sb:author><ce:given-name>M.A.</ce:given-name><ce:surname>Medina</ce:surname></sb:author><sb:author><ce:given-name>X.F.</ce:given-name><ce:surname>Huang</ce:surname></sb:author><sb:author><ce:given-name>S.M.</ce:given-name><ce:surname>Dorta-Estremera</ce:surname></sb:author><sb:author><ce:given-name>N.R.</ce:given-name><ce:surname>Greeley</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Nitti</ce:surname></sb:author><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Peng</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Liu</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Lou</ce:surname></sb:author><sb:author><ce:given-name>Z.</ce:given-name><ce:surname>Wang</ce:surname></sb:author><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Ma</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Rabinovich</ce:surname></sb:author><sb:author><ce:given-name>K.S.</ce:given-name><ce:surname>Schluns</ce:surname></sb:author><sb:author><ce:given-name>R.E.</ce:given-name><ce:surname>Davis</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Hwu</ce:surname></sb:author><sb:author><ce:given-name>W.W.</ce:given-name><ce:surname>Overwijk</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Persistent antigen at vaccination sites induces tumor-specific CD8<ce:sup loc="post">+</ce:sup> T cell sequestration, dysfunction and deletion</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nat. Med.</sb:maintitle></sb:title><sb:volume-nr>19</sb:volume-nr></sb:series><sb:date>2013</sb:date></sb:issue><sb:pages><sb:first-page>465</sb:first-page><sb:last-page>472</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0210"><ce:label>[42]</ce:label><sb:reference id="rf0210"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>G.G.</ce:given-name><ce:surname>Kenter</ce:surname></sb:author><sb:author><ce:given-name>M.J.</ce:given-name><ce:surname>Welters</ce:surname></sb:author><sb:author><ce:given-name>A.R.</ce:given-name><ce:surname>Valentijn</ce:surname></sb:author><sb:author><ce:given-name>M.J.</ce:given-name><ce:surname>Lowik</ce:surname></sb:author><sb:author><ce:given-name>D.M.</ce:given-name><ce:surname>Berends-van der Meer</ce:surname></sb:author><sb:author><ce:given-name>A.P.</ce:given-name><ce:surname>Vloon</ce:surname></sb:author><sb:author><ce:given-name>J.W.</ce:given-name><ce:surname>Drijfhout</ce:surname></sb:author><sb:author><ce:given-name>A.R.</ce:given-name><ce:surname>Wafelman</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Oostendorp</ce:surname></sb:author><sb:author><ce:given-name>G.J.</ce:given-name><ce:surname>Fleuren</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Offringa</ce:surname></sb:author><sb:author><ce:given-name>S.H.</ce:given-name><ce:surname>van der Burg</ce:surname></sb:author><sb:author><ce:given-name>C.J.</ce:given-name><ce:surname>Melief</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Clin. Cancer Res.</sb:maintitle></sb:title><sb:volume-nr>14</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>169</sb:first-page><sb:last-page>177</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0215"><ce:label>[43]</ce:label><sb:reference id="rf0215"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>G.G.</ce:given-name><ce:surname>Kenter</ce:surname></sb:author><sb:author><ce:given-name>M.J.</ce:given-name><ce:surname>Welters</ce:surname></sb:author><sb:author><ce:given-name>A.R.</ce:given-name><ce:surname>Valentijn</ce:surname></sb:author><sb:author><ce:given-name>M.J.</ce:given-name><ce:surname>Lowik</ce:surname></sb:author><sb:author><ce:given-name>D.M.</ce:given-name><ce:surname>Berends-van der Meer</ce:surname></sb:author><sb:author><ce:given-name>A.P.</ce:given-name><ce:surname>Vloon</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Essahsah</ce:surname></sb:author><sb:author><ce:given-name>L.M.</ce:given-name><ce:surname>Fathers</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Offringa</ce:surname></sb:author><sb:author><ce:given-name>J.W.</ce:given-name><ce:surname>Drijfhout</ce:surname></sb:author><sb:author><ce:given-name>A.R.</ce:given-name><ce:surname>Wafelman</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Oostendorp</ce:surname></sb:author><sb:author><ce:given-name>G.J.</ce:given-name><ce:surname>Fleuren</ce:surname></sb:author><sb:author><ce:given-name>S.H.</ce:given-name><ce:surname>van der Burg</ce:surname></sb:author><sb:author><ce:given-name>C.J.</ce:given-name><ce:surname>Melief</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>N. Engl. J. Med.</sb:maintitle></sb:title><sb:volume-nr>361</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>1838</sb:first-page><sb:last-page>1847</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0220"><ce:label>[44]</ce:label><sb:reference id="rf0220"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>C.J.</ce:given-name><ce:surname>Melief</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Synthetic vaccine for the treatment of lesions caused by high risk human papilloma virus</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cancer J.</sb:maintitle></sb:title><sb:volume-nr>17</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>300</sb:first-page><sb:last-page>301</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0225"><ce:label>[45]</ce:label><sb:reference id="rf0225"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>T.T.</ce:given-name><ce:surname>Beaudette</ce:surname></sb:author><sb:author><ce:given-name>E.M.</ce:given-name><ce:surname>Bachelder</ce:surname></sb:author><sb:author><ce:given-name>J.A.</ce:given-name><ce:surname>Cohen</ce:surname></sb:author><sb:author><ce:given-name>A.C.</ce:given-name><ce:surname>Obermeyer</ce:surname></sb:author><sb:author><ce:given-name>K.E.</ce:given-name><ce:surname>Broaders</ce:surname></sb:author><sb:author><ce:given-name>J.M.</ce:given-name><ce:surname>Frechet</ce:surname></sb:author><sb:author><ce:given-name>E.S.</ce:given-name><ce:surname>Kang</ce:surname></sb:author><sb:author><ce:given-name>I.</ce:given-name><ce:surname>Mende</ce:surname></sb:author><sb:author><ce:given-name>W.W.</ce:given-name><ce:surname>Tseng</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Davidson MG and Engleman EG: <ce:italic>in vivo</ce:italic> studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mol. Pharm.</sb:maintitle></sb:title><sb:volume-nr>6</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>1160</sb:first-page><sb:last-page>1169</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0230"><ce:label>[46]</ce:label><sb:reference id="rf0230"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.R.</ce:given-name><ce:surname>Kammer</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Amacker</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Rasi</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Westerfeld</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Gremion</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Neuhaus</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Zurbriggen</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Vaccine</sb:maintitle></sb:title><sb:volume-nr>25</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>7065</sb:first-page><sb:last-page>7074</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0235"><ce:label>[47]</ce:label><sb:reference id="rf0235"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Z.</ce:given-name><ce:surname>Cui</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Huang</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cancer Immunol. Immunother.</sb:maintitle></sb:title><sb:volume-nr>54</sb:volume-nr></sb:series><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>1180</sb:first-page><sb:last-page>1190</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0240"><ce:label>[48]</ce:label><sb:reference id="rf0240"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Chen</ce:surname></sb:author><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Yan</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Huang</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>A simple but effective cancer vaccine consisting of an antigen and a cationic lipid</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cancer Immunol. Immunother.</sb:maintitle></sb:title><sb:volume-nr>57</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>517</sb:first-page><sb:last-page>530</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0245"><ce:label>[49]</ce:label><sb:reference id="rf0245"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>W.</ce:given-name><ce:surname>Chen</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Huang</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mol. Pharm.</sb:maintitle></sb:title><sb:volume-nr>5</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>464</sb:first-page><sb:last-page>471</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0250"><ce:label>[50]</ce:label><sb:reference id="rf0250"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.G.</ce:given-name><ce:surname>Tovey</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Lallemand</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Adjuvant activity of cytokines</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Methods Mol. Biol.</sb:maintitle></sb:title><sb:volume-nr>626</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>287</sb:first-page><sb:last-page>309</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0255"><ce:label>[51]</ce:label><sb:reference id="rf0255"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Lapteva</ce:surname></sb:author><sb:author><ce:given-name>X.F.</ce:given-name><ce:surname>Huang</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>CCL5 as an adjuvant for cancer immunotherapy</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Expert. Opin. Biol. Ther.</sb:maintitle></sb:title><sb:volume-nr>10</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>725</sb:first-page><sb:last-page>733</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0260"><ce:label>[52]</ce:label><sb:reference id="rf0260"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.S.</ce:given-name><ce:surname>Duthie</ce:surname></sb:author><sb:author><ce:given-name>H.P.</ce:given-name><ce:surname>Windish</ce:surname></sb:author><sb:author><ce:given-name>C.B.</ce:given-name><ce:surname>Fox</ce:surname></sb:author><sb:author><ce:given-name>S.G.</ce:given-name><ce:surname>Reed</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Use of defined TLR ligands as adjuvants within human vaccines</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Immunol. Rev.</sb:maintitle></sb:title><sb:volume-nr>239</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>178</sb:first-page><sb:last-page>196</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0265"><ce:label>[53]</ce:label><sb:reference id="rf0265"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Celis</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Toll-like receptor ligands energize peptide vaccines through multiple paths</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cancer Res.</sb:maintitle></sb:title><sb:volume-nr>67</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>7945</sb:first-page><sb:last-page>7947</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0270"><ce:label>[54]</ce:label><sb:reference id="rf0340"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.T.</ce:given-name><ce:surname>Evans</ce:surname></sb:author><sb:author><ce:given-name>C.W.</ce:given-name><ce:surname>Cluff</ce:surname></sb:author><sb:author><ce:given-name>D.A.</ce:given-name><ce:surname>Johnson</ce:surname></sb:author><sb:author><ce:given-name>M.J.</ce:given-name><ce:surname>Lacy</ce:surname></sb:author><sb:author><ce:given-name>D.H.</ce:given-name><ce:surname>Persing</ce:surname></sb:author><sb:author><ce:given-name>J.R.</ce:given-name><ce:surname>Baldridge</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Enhancement of antigen-specific immunity <ce:italic>via</ce:italic> the TLR4 ligands MPL adjuvant and Ribi.529</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Expert Rev. Vaccines</sb:maintitle></sb:title><sb:volume-nr>2</sb:volume-nr></sb:series><sb:date>2003</sb:date></sb:issue><sb:pages><sb:first-page>219</sb:first-page><sb:last-page>229</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0275"><ce:label>[55]</ce:label><sb:reference id="rf0270"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Steinhagen</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Kinjo</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Bode</ce:surname></sb:author><sb:author><ce:given-name>D.M.</ce:given-name><ce:surname>Klinman</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>TLR-based immune adjuvants</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Vaccine</sb:maintitle></sb:title><sb:volume-nr>29</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>3341</sb:first-page><sb:last-page>3355</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0280"><ce:label>[56]</ce:label><sb:reference id="rf0275"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.C.</ce:given-name><ce:surname>Steere</ce:surname></sb:author><sb:author><ce:given-name>V.K.</ce:given-name><ce:surname>Sikand</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Meurice</ce:surname></sb:author><sb:author><ce:given-name>D.L.</ce:given-name><ce:surname>Parenti</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Fikrig</ce:surname></sb:author><sb:author><ce:given-name>R.T.</ce:given-name><ce:surname>Schoen</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Nowakowski</ce:surname></sb:author><sb:author><ce:given-name>C.H.</ce:given-name><ce:surname>Schmid</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Laukamp</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Buscarino</ce:surname></sb:author><sb:author><ce:given-name>D.S.</ce:given-name><ce:surname>Krause</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>N. Engl. J. Med.</sb:maintitle></sb:title><sb:volume-nr>339</sb:volume-nr></sb:series><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>209</sb:first-page><sb:last-page>215</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0285"><ce:label>[57]</ce:label><sb:reference id="rf0280"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Garcon</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Segal</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Tavares</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Van Mechelen</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The safety evaluation of adjuvants during vaccine development: the AS04 experience</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Vaccine</sb:maintitle></sb:title><sb:volume-nr>29</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>4453</sb:first-page><sb:last-page>4459</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0290"><ce:label>[58]</ce:label><sb:reference id="rf0285"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Burke</ce:surname></sb:author><sb:author><ce:given-name>V.R.</ce:given-name><ce:surname>Gomez-Roman</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Lian</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Sun</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Kan</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Ulmer</ce:surname></sb:author><sb:author><ce:given-name>I.K.</ce:given-name><ce:surname>Srivastava</ce:surname></sb:author><sb:author><ce:given-name>S.W.</ce:given-name><ce:surname>Barnett</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Virology</sb:maintitle></sb:title><sb:volume-nr>387</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>147</sb:first-page><sb:last-page>156</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0295"><ce:label>[59]</ce:label><sb:reference id="rf0290"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Verthelyi</ce:surname></sb:author><sb:author><ce:given-name>V.W.</ce:given-name><ce:surname>Wang</ce:surname></sb:author><sb:author><ce:given-name>J.D.</ce:given-name><ce:surname>Lifson</ce:surname></sb:author><sb:author><ce:given-name>D.M.</ce:given-name><ce:surname>Klinman</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>AIDS</sb:maintitle></sb:title><sb:volume-nr>18</sb:volume-nr></sb:series><sb:date>2004</sb:date></sb:issue><sb:pages><sb:first-page>1003</sb:first-page><sb:last-page>1008</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0300"><ce:label>[60]</ce:label><sb:reference id="rf0295"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>G.J.</ce:given-name><ce:surname>Weiner</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>CpG oligodeoxynucleotide-based therapy of lymphoid malignancies</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Adv. Drug Deliv. Rev.</sb:maintitle></sb:title><sb:volume-nr>61</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>263</sb:first-page><sb:last-page>267</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0305"><ce:label>[61]</ce:label><sb:reference id="rf0300"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Carpentier</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Laigle-Donadey</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Zohar</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Capelle</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Behin</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Tibi</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Martin-Duverneuil</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Sanson</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Lacomblez</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Taillibert</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Puybasset</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Van Effenterre</ce:surname></sb:author><sb:author><ce:given-name>J.Y.</ce:given-name><ce:surname>Delattre</ce:surname></sb:author><sb:author><ce:given-name>A.F.</ce:given-name><ce:surname>Carpentier</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neuro. Oncol.</sb:maintitle></sb:title><sb:volume-nr>8</sb:volume-nr></sb:series><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>60</sb:first-page><sb:last-page>66</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0310"><ce:label>[62]</ce:label><sb:reference id="rf0305"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Mukherjee</ce:surname></sb:author><sb:author><ce:given-name>L.B.</ce:given-name><ce:surname>Pathangey</ce:surname></sb:author><sb:author><ce:given-name>J.B.</ce:given-name><ce:surname>Bradley</ce:surname></sb:author><sb:author><ce:given-name>T.L.</ce:given-name><ce:surname>Tinder</ce:surname></sb:author><sb:author><ce:given-name>G.D.</ce:given-name><ce:surname>Basu</ce:surname></sb:author><sb:author><ce:given-name>E.T.</ce:given-name><ce:surname>Akporiaye</ce:surname></sb:author><sb:author><ce:given-name>S.J.</ce:given-name><ce:surname>Gendler</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Vaccine</sb:maintitle></sb:title><sb:volume-nr>25</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>1607</sb:first-page><sb:last-page>1618</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0315"><ce:label>[63]</ce:label><sb:reference id="rf0310"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Sen</ce:surname></sb:author><sb:author><ce:given-name>Q.</ce:given-name><ce:surname>Chen</ce:surname></sb:author><sb:author><ce:given-name>C.M.</ce:given-name><ce:surname>Snapper</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Immunization of aged mice with a pneumococcal conjugate vaccine combined with an unmethylated CpG-containing oligodeoxynucleotide restores defective immunoglobulin G antipolysaccharide responses and specific CD4<ce:hsp sp="0.10"/>+−<ce:hsp sp="0.10"/>T-cell priming to young adult levels</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Infect. Immun.</sb:maintitle></sb:title><sb:volume-nr>74</sb:volume-nr></sb:series><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>2177</sb:first-page><sb:last-page>2186</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0320"><ce:label>[64]</ce:label><sb:reference id="rf0315"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>C.C.</ce:given-name><ce:surname>Amaral</ce:surname></sb:author><sb:author><ce:given-name>I.P.</ce:given-name><ce:surname>Garcia</ce:surname></sb:author><sb:author><ce:given-name>G.F.</ce:given-name><ce:surname>Fernandes</ce:surname></sb:author><sb:author><ce:given-name>S.R.</ce:given-name><ce:surname>Almeida</ce:surname></sb:author><sb:author><ce:given-name>Z.P.</ce:given-name><ce:surname>Camargo</ce:surname></sb:author><sb:author><ce:given-name>M.C.</ce:given-name><ce:surname>Souza</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Adjuvant effect of synthetic oligodeoxyribonucleotides (CpG-ODN) from the <ce:italic>Paracoccidioides brasiliensis</ce:italic> gp43 gene on the Th2–Th1 immunomodulation of experimental paracoccidioidomycosis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Scand. J. Immunol.</sb:maintitle></sb:title><sb:volume-nr>62</sb:volume-nr></sb:series><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>325</sb:first-page><sb:last-page>333</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0325"><ce:label>[65]</ce:label><sb:reference id="rf0320"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Daftarian</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Mansour</ce:surname></sb:author><sb:author><ce:given-name>A.C.</ce:given-name><ce:surname>Benoit</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Pohajdak</ce:surname></sb:author><sb:author><ce:given-name>D.W.</ce:given-name><ce:surname>Hoskin</ce:surname></sb:author><sb:author><ce:given-name>R.G.</ce:given-name><ce:surname>Brown</ce:surname></sb:author><sb:author><ce:given-name>W.M.</ce:given-name><ce:surname>Kast</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Vaccine</sb:maintitle></sb:title><sb:volume-nr>24</sb:volume-nr></sb:series><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>5235</sb:first-page><sb:last-page>5244</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0330"><ce:label>[66]</ce:label><sb:reference id="rf0325"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.G.</ce:given-name><ce:surname>Chandy</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Nurkkala</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Josefsson</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Eriksson</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Vaccine</sb:maintitle></sb:title><sb:volume-nr>25</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>6037</sb:first-page><sb:last-page>6046</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0335"><ce:label>[67]</ce:label><sb:reference id="rf0330"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.L.</ce:given-name><ce:surname>Cerutti</ce:surname></sb:author><sb:author><ce:given-name>L.G.</ce:given-name><ce:surname>Alonso</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Tatti</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>de Prat-Gay</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Long-lasting immunoprotective and therapeutic effects of a hyperstable E7 oligomer based vaccine in a murine human papillomavirus tumor model</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Int. J. Cancer</sb:maintitle></sb:title><sb:volume-nr>130</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>1813</sb:first-page><sb:last-page>1820</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0340"><ce:label>[68]</ce:label><sb:reference id="rf0335"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Mansilla</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Berraondo</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Durantez</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Martinez</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Casares</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Arribillaga</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Rudilla</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Fioravanti</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Lozano</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Villanueva</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Sarobe</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Borras</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Leclerc</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Prieto</ce:surname></sb:author><sb:author><ce:given-name>J.J.</ce:given-name><ce:surname>Lasarte</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Int. J. Cancer</sb:maintitle></sb:title><sb:volume-nr>131</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>641</sb:first-page><sb:last-page>651</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference></ce:bibliography-sec></ce:bibliography></tail></article></xocs:serial-item></xocs:doc></originalText></full-text-retrieval-response>